Document:

EX-4.5

 Exhibit 4.5 

Form of Representatives’ Warrant Agreement 

THE REGISTERED HOLDER OF THIS WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS WARRANT EXCEPT AS HEREIN PROVIDED AND
THE REGISTERED HOLDER OF THIS WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) THINKEQUITY,
A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC., H.C. WAINWRIGHT & CO., LLC OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF THINKEQUITY, A DIVISION OF FORDHAM FINANCIAL
MANAGEMENT, INC., H.C. WAINWRIGHT & CO., LLC OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER. 
 THIS WARRANT IS NOT EXERCISABLE PRIOR TO
[                    ]1. VOID AFTER 5:00 P.M., EASTERN TIME,
[                    ]2. 

WARRANT TO PURCHASE COMMON STOCK 

ALZHEON, INC. 
 Warrant
Shares:                     
 Initial
Exercise Date:             , 2018 
 THIS WARRANT TO PURCHASE COMMON STOCK (the
“Warrant”) certifies that, for value received,                     , or its assigns (the “Holder”) is entitled,
upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after             , 2018 (the “Initial Exercise Date”)
and, in accordance with FINRA Rule 5110(f)(2)(G)(i), prior to at 5:00 p.m. (New York time) on the date that is three (3) years following the Effective Date (the “Termination Date”) but not thereafter, to subscribe for and
purchase from Alzheon, Inc., a Delaware corporation (the “Company”), up to             shares of Common Stock, par value $0.001 per share, of the Company (the
“Warrant Shares”), as subject to adjustment hereunder. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). Terms not defined herein shall have the
meanings ascribed to them in the Underwriting Agreement between ThinkEquity, a division of Fordham Financial Management, Inc. and H.C. Wainwright & Co. LLC as representatives of the underwriters set forth therein and the Company, dated as
of                     , 2018 (the “Underwriting Agreement”). 

Section 1. Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms
have the meanings indicated in this Section 1: 
  

	1 	 Date that is one year from the effective date of the offering 

	2 	 Date that is three years from the effective date of the offering 

 “Affiliate” means any Person that, directly or indirectly
through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act. 

“Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the
United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. 

“Commission” means the United States Securities and Exchange Commission. 

“Effective Date” means the date on which the registration statement on Form
S-1 (File No. 333-227057) is declared effective by the Commission. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. 
 “Person” means an individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 

“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be
amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. 

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 “Trading Day” means a day on which the New York Stock Exchange is open for trading. 

“Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or
quoted for trading on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing). 

“VWAP” means, for any date, the price determined by the first of the following clauses that applies:
(a) if the Common Stock is listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted
as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not listed or quoted on a Trading Market and is listed or quoted on the OTCQB or OTCQX, the
volume weighted average price of a share of Common Stock for such date (or the nearest preceding date) on the OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on a Trading Market or the OTCQB or
OTCQX and if prices for Common Stock are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of
Common Stock so reported, or (d) in all other cases, the fair market value of the Common Stock as determined by the board of directors of the Company and reasonably acceptable to the Holder. 

 Section 2. Exercise. 

a) Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or
after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing
on the books of the Company) of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise Form annexed hereto. Within two (2) Trading Days following the date of exercise as
aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in
Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise form be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available
hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within five (5) Trading Days of the date the final Notice of Exercise is delivered to the Company.
Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to
the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise
Form within two (2) Business Days of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the
Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof. 

b) Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be
$                    , subject to adjustment hereunder (the “Exercise Price”). 

c) Cashless Exercise. If at any time on or after the Initial Exercise Date, there is no effective registration statement
registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which
the Holder shall be entitled to receive the number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where: 

 

	 	(A) =	 the VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by
means of a “cashless exercise,” as set forth in the applicable Notice of Exercise; 

  

	 	(B) =	 the Exercise Price of this Warrant, as adjusted hereunder; and 

 

	 	(X) =	 the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms
of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. 

 If
Warrant Shares are issued in such a “cashless exercise,” the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants
being exercised, and the holding period of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to this Section 2(c).

 Notwithstanding anything herein to the contrary, on the Termination Date,
this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c). 
 d) Mechanics of
Exercise. 
 i. Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased
hereunder to be transmitted by its transfer agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system
(“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder, or
(B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 and, in either case, the Warrant
Shares have been sold by the Holder prior to the Warrant Share Delivery Date (as defined below) pursuant to such effective registration statement or in compliance with Rule 144, as applicable, and otherwise by physical delivery of a certificate or
book entry with the Company’s transfer agent, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address
specified by the Holder in the Notice of Exercise by the date that is two (2) Trading Days after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”) so long as the payment for
such exercise has been made on or prior to the Warrant Share Delivery Date. If the Warrant Shares can be delivered via DWAC, the transfer agent shall have received from the Company, at the expense of the Company, any legal opinions or other
documentation required by it to deliver such Warrant Shares without legend (subject to receipt by the Company of reasonable back up documentation from the Holder, including with respect to affiliate status) and, if applicable and requested by the
Company prior to the Warrant Share Delivery Date, the transfer agent shall have received from the Holder a confirmation of sale of the Warrant Shares (provided the requirement of the Holder to provide a confirmation as to the sale of Warrant Shares
shall not be applicable to the issuance of unlegended Warrant Shares upon a cashless exercise of this Warrant if the Warrant Shares are then eligible for resale pursuant to Rule 144(b)(1)). The Warrant Shares shall be deemed to have been issued, and
Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise Price (or by
cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) prior to the issuance of such shares, having been paid.      

ii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at
the request of the Holder and upon surrender of this Warrant, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this
Warrant, which new Warrant shall in all other respects be identical with this Warrant. 

 iii. Rescission Rights. If the Company fails to cause its transfer
agent to deliver to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise; provided, however, that the Holder shall be required
to return any Warrant Shares or Common Stock subject to any such rescinded exercise notice concurrently with the return to Holder of the aggregate Exercise Price paid to the Company for such Warrant Shares and the restoration of Holder’s right
to acquire such Warrant Shares pursuant to this Warrant (including, issuance of a replacement warrant evidencing such restored right). 

iv. Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon
Exercise. In addition to any other rights available to the Holder, if the Company fails to cause its transfer agent to transmit to the Holder the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery Date, and if after
such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant
Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the
Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and
equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely
complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise
of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide
the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a
Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver
shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. 
 v. No Fractional Shares
or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price. 

 vi. Charges, Taxes and Expenses. Issuance of Warrant Shares shall be
made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in
the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The
Company shall pay all transfer agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar
functions) required for same-day electronic delivery of the Warrant Shares. 
 vii.
Closing of Books. The Company will not close its stockholder books or records in any manner to intentionally prevent the timely exercise of this Warrant, pursuant to the terms hereof. 

viii. Signature. This Section 2 and the exercise form attached hereto set forth the totality of the procedures
required of the Holder in order to exercise this Warrant. Without limiting the preceding sentences, no ink-original exercise form shall be required, nor shall any medallion guarantee (or other type of
guarantee or notarization) of any exercise form be required in order to exercise this Warrant. No additional legal opinion, other information or instructions shall be required of the Holder to exercise this Warrant. The Company shall honor
exercises of this Warrant and shall deliver Warrant Shares underlying this Warrant in accordance with the terms, conditions and time periods set forth herein. 

e) Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the
Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the
foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being
made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise or
conversion of the unexercised or nonconverted portion of any other securities of the Company subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such 

 
calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that
the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
together with any Affiliates) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In
addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in
determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the
case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Company’s transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written
or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be
determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The
“Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership
Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in
strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

Section 3. Certain Adjustments. 

a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock
dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common
Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a
smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the
number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this 

 
Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification. For the purposes of clarification, the Exercise Price of this Warrant will not be adjusted in the event that the Company or any Subsidiary thereof, as applicable, sells or grants any option to
purchase, or sells or grants any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or Common Stock Equivalents, at an effective price per share
less than the Exercise Price then in effect. 
 b) [RESERVED] 

c) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the
Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the
Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right to participate
in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock
as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation). 
 d) Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall
declare or make any dividend (other than cash dividends) or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any
distribution of shares or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the
issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, to the extent that the Holder’s right to
participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of
Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the
Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the
Holder has exercised this Warrant. 

 e) Fundamental Transaction. If, at any time while this Warrant is
outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease,
license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the
Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock
is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the
outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement
or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such
exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor
or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable by holders of Common Stock as a result of such Fundamental Transaction for
each share of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the
determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The
Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant in accordance with
the provisions of this Section 3(e) and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to
this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard
to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the
shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic

 
value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any
such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall refer instead to
the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. 

f) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of
a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if
any) issued and outstanding. 
 g) Notice to Holder. 

i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this
Section 3, the Company shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring
such adjustment. 
 ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any
other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common
Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock,
any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or
property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed a notice to the Holder at its last address
as it shall appear upon the Warrant Register of the Company, at least fifteen (15) calendar days prior to the applicable record or effective date hereinafter specified, stating (x) the date on which a record is to be taken for the purpose
of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to
be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record
shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to provide such notice
or any defect therein shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material,
non-public information regarding the Company or any of the Subsidiaries, the 

 
Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise
this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. 

iii. No Requirement for Written Notice to Holder. The Company shall be considered to have met all of its obligations to
provide notice to the Holder under this Section 3 if the transaction giving rise to the Company’s obligations under this Section 3 is disclosed via a press release, a public filing by the Company with the Commission, or other means of
public dissemination. 
 Section 4. Transfer of Warrant. 

a) Transferability. Pursuant to FINRA Rule 5110(g)(1), neither this Warrant nor any Warrant Shares issued upon exercise
of this Warrant shall be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any
person for a period of 180 days immediately following the date of effectiveness or commencement of sales of the offering pursuant to which this Warrant is being issued, except the transfer of any security: 

i. by operation of law or by reason of reorganization of the Company; 

ii. to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so
transferred remain subject to the lock-up restriction in this Section 4(a) for the remainder of the time period; 

iii. if the aggregate amount of securities of the Company held by the Holder or related person do not exceed 1% of the
securities being offered; 
 iv. that is beneficially owned on a pro-rata basis by
all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the equity in the fund; or 

v. the exercise or conversion of any security, if all securities received remain subject to the
lock-up restriction in this Section 4(a) for the remainder of the time period. 

Subject to the foregoing restriction, any applicable securities laws and the conditions set forth in Section 4(d), this
Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the
assignor a new Warrant 

 
evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to
physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date the Holder delivers an
assignment form to the Company assigning this Warrant full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued. 

b) New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid
office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer
which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers
or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto. 

c) Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. 
 d) Representation by
the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or
for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act. 

Section 5. Registration Rights. 

(a) Demand Registration. 

(i) Grant of Right. The Company, upon written demand (a “Demand Notice”) of the Holders of at least 51% of the Warrants
and/or the underlying Warrant Shares (“Majority Holders”), agrees to register, on one occasion, all or any portion of the Warrant Shares underlying the Warrants (collectively, the “Registrable Securities”). On such
occasion, the Company will file a registration statement with the Commission covering the Registrable Securities within sixty (60) days after receipt of a Demand Notice and use its commercially reasonable efforts to have the registration
statement declared effective promptly thereafter, subject to compliance with review by the Commission. The demand for registration may be made at any time during a period of four (4) years beginning on the date that is one (1) year from
the Effective Date. The Company covenants and agrees to give written notice of its receipt of any Demand Notice by any Holders to all other registered Holders of the Warrants and/or the Registrable Securities within ten (10) days after the date
of the receipt of any such Demand Notice. 

 (ii) Terms. The Company shall bear all fees and expenses attendant to the
registration of the Registrable Securities pursuant to Section 5(a)(i), but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent them in connection with the sale
of the Registrable Securities. The Company agrees to use its commercially reasonable efforts to cause the filing required herein to become effective promptly and to qualify or register the Registrable Securities in such States as are reasonably
requested by the Holders; provided, however, that in no event shall the Company be required to register the Registrable Securities in a State in which such registration would cause: (i) the Company to be obligated to register or
license to do business in such State or submit to general service of process in such State, or (ii) the principal stockholders of the Company to be obligated to escrow their shares of capital stock of the Company. The Company shall cause any
registration statement filed pursuant to the demand right granted under Section 5(a)(i) to remain effective for a period of at least twelve (12) consecutive months after the date that the Holders of the Registrable Securities covered by
such registration statement are first given the opportunity to sell all of such securities. The Holders shall only use the prospectuses provided by the Company to sell the shares covered by such registration statement, and will immediately cease to
use any prospectus furnished by the Company if the Company advises the Holder that such prospectus may no longer be used due to a material misstatement or omission. Notwithstanding the provisions of this Section 5(a)(ii), the Holder shall be
entitled to a demand registration under this Section 5(a)(ii) on only one (1) occasion and such demand registration right shall terminate on the fifth anniversary of the Effective Date in accordance with FINRA Rule 5110(f)(2)(G)(iv). 

(b) General Terms. 
 (i)
Exercise of Warrants. Nothing contained in this Warrant shall be construed as requiring the Holders to exercise their Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof. 

(ii) Documents Delivered to Holders. The Company shall furnish to each Holder participating in any of the foregoing offerings and to
each underwriter of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of counsel to the Company, dated the effective date of such registration statement (and, if such registration
includes an underwritten public offering, an opinion dated the date of the closing under any underwriting agreement related thereto), and (ii) a “cold comfort” letter dated the effective date of such registration statement (and, if
such registration includes an underwritten public offering, a letter dated the date of the closing under the underwriting agreement) signed by the independent registered public accounting firm which has issued a report on the Company’s
financial statements included in such registration statement, in each case covering substantially the same matters with respect to such registration statement (and the prospectus included therein) and, in the case of such accountants’ letter,
with respect to events subsequent to the date of such financial statements, as are customarily covered in opinions of issuer’s counsel and in accountants’ letters delivered to underwriters in underwritten public offerings of securities.
The Company shall also deliver promptly to each Holder participating in the offering requesting the correspondence and memoranda described below and to the managing underwriter, if any, copies of all correspondence between the Commission and the
Company, its counsel or auditors and all memoranda relating to discussions with the Commission or its staff with respect to the registration statement and permit each Holder and underwriter to do such investigation, upon reasonable advance notice,
with respect to information contained in or omitted from the registration statement as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation shall include access to books, records and
properties and opportunities to discuss the business of the Company with its officers and independent auditors, all to such reasonable extent and at such reasonable times as any such Holder shall reasonably request. 

(iii) Documents to be Delivered by Holders. Each of the Holders participating in any of the foregoing offerings shall furnish to the
Company a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security holders. 

 Section 6. Miscellaneous. 

a) No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or
other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i). 
 b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any certificate relating to
the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant
or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. 

c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any
right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day. 

d) Authorized Shares. 

The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority
to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant
Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued
upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid
and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). 

Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of the Holder as set
forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such
increase in par value, (ii) take all such action 

 
as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use
commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant. 

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is
exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. 

e) Jurisdiction. This Warrant shall be governed by and construed and enforced in accordance with the internal laws of
the State of New York, without regard to the principles of conflicts of law thereof that would result in the application of the laws of any other jurisdiction. 

f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not
registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws. 

g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of
Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to
comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable
attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. 

h) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the
Company shall be delivered in accordance with the notice provisions of the Underwriting Agreement. 
 i) Limitation of
Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. 

j) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of
damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and
hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. 

k) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from
time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. 

 l) Amendment. This Warrant may be modified or amended or the
provisions hereof waived only by the written consent of the Company and the Holder. 
 m) Severability. Wherever
possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be
ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant. 

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose,
be deemed a part of this Warrant. 
 ******************** 

(Signature Page Follows) 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer
thereunto duly authorized as of the date first above indicated. 
  

	
	 ALZHEON, INC. 
  

	
By:                         
                                         
                              

       Name:

       Title:

 NOTICE OF EXERCISE 

TO: ALZHEON, INC. 

                       
                          

(1) The undersigned hereby elects to purchase
                    Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith
payment of the exercise price in full, together with all applicable transfer taxes, if any. 
 (2) Payment shall take the form of (check
applicable box): 
 [ ] in lawful money of the United States; or 

[ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c). 

(3) Please register and issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: 

                       
                      
 The Warrant Shares
shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to: 
  

                       
                      
  

                       
                      
  

                       
                      

(4) Accredited Investor. The undersigned represents and warrants that is an “accredited investor” as defined in
Regulation D promulgated under the Securities Act of 1933, as amended. 
 [SIGNATURE OF HOLDER] 

 

	
	Name of Investing
Entity:                                        
                                         
                                         
                                         
                                         
   
	
	Signature of Authorized Signatory of Investing
Entity:                                       
                                         
                                         
                                 
	
	Name of Authorized
Signatory:                                       
                                         
                                         
                                         
                                   
	
	Title of Authorized
Signatory:                                       
                                         
                                         
                                         
                                     
	
	Date:                                     
                                         
                                         
                                         
                                         
                                         
     

 ASSIGNMENT FORM 

(To assign the foregoing warrant, execute 

this form and supply required information. 

Do not use this form to exercise the warrant.) 

FOR VALUE RECEIVED, [            ] all of or
[            ] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to 

_______________________________________________ whose address is 
  

			
	                                      
                                         
                                         
       .	  	
		
	                                      
                                         
                                         
        	  	

 Dated: ______________,
_______                             

Holder’s Signature: _____________________________ 

Holder’s Address: _____________________________ 

                        
                                         
                        
 NOTE: The
signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever. Officers of corporations and those acting in a fiduciary or other representative
capacity should file proper evidence of authority to assign the foregoing Warrant.EX-10.10

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit 10.10 

Execution Version 

LICENSE AGREEMENT 
 This License Agreement
(this “Agreement”) is made effective as of October 22, 2013 (the “Effective Date”). 
  

			
	
BETWEEN:                  
                                  
	  	FB HEALTH S.p.A., a company existing under the laws of Italy
		
		  	(hereinafter referred to as the “Licensor”)
		
	 AND:
	  	ALZHEON, INC., a company existing under the laws of the state of Delaware
		
		  	(hereinafter referred to as “Alzheon”)
		
		  	(the Licensor and Alzheon are each hereafter referred to individually as a “Party” and together as the “Parties”).

 WHEREAS, the Licensor is the owner of, or otherwise Controls (including pursuant to that certain
License Agreement by and between the Licensor and BHI Limited Partnership (“Bellus”), of even date herewith (the “Bellus License Agreement”)), certain patents, patent applications, technology, know-how and scientific and technical information relating to the Licensed Products (as such term is defined below); 

WHEREAS, Alzheon desires to obtain the exclusive right from the Licensor to Develop, make, modify, enhance, improve and use such
patents, patent applications, technology, know-how and scientific and technical information for the Field, and manufacture, market, sell, offer for sale, import, distribute and use the Licensed Products in the
Territory in the Field, and to obtain certain other rights of the Licensor under the Bellus License Agreement; 
 WHEREAS, the
Licensor and Alzheon are parties to that certain Letter Agreement with Bellus, of even date herewith, (the “Letter Agreement”), which, among other things, clarifies the rights and obligations of the Licensor, Bellus and Alzheon with
respect to this Agreement and the Bellus License Agreement; and 
 WHEREAS, the Licensor desires to grant such rights to Alzheon on
the terms and conditions of this Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and
for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree as follows: 

  
 1. 

	1.	 DEFINITIONS 

Whenever used in this Agreement with an initial capital letter, the terms defined in this Article 1 shall have the meanings specified. 

“Action” shall have the meaning for such term set forth in Section 7.6. 

“Affiliate” shall mean, with respect to a Party or a Third Party, any corporation, firm, limited liability company, partnership or other
entity which directly controls or is controlled by or is under common control with such Party or Third Party. “Control”, for purposes of this definition only, means ownership, directly or indirectly through one or more Affiliates, of fifty
percent (50%) or more of the shares entitled to vote for the election of directors, in the case of a corporation, or fifty percent (50%) or more of the equity interests in the case of any other type of legal entity, status as a general partner in
any partnership, or any other arrangement whereby such Party or Third Party controls or has the right to control the Board of Directors or equivalent governing body of a corporation or other entity. 

“Alzheon” shall have the meaning for such term set forth in the Recitals. 

“Alzheon Indemnitees” shall have the meaning for such term set forth in Section 10.2. 

“Auditing Party” shall have the meaning for such term set forth in Section 4.5.2. 

“Bankruptcy Code” shall mean Title 11 of the United States Code, as amended. 

“Bellus” shall have the meaning for such term set forth in the Recitals. 

“Bellus License Agreement” shall have the meaning for such term set forth in the Recitals. 

“BLU8499 Patent Rights” shall have the meaning for such term set forth in Section 7.1.1. 

“Celtic Agreement” shall have the meaning for such term set forth in Section 8.1.18. 

“Change of Control” means, with respect to a Party, (a) a bona fide merger, consolidation, business combination, recapitalization,
liquidation, dissolution or similar transaction or series of related transactions involving the Party and a Third Party pursuant to which the stockholders of the Party immediately preceding such transaction or transactions hold less than a majority
of the equity interests in the surviving or resulting entity of such transaction or transactions; (b) any Third Party “person” (as such term is used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended)
becomes a “beneficial owner” (as such term is defined in Rule 13d-3 promulgated under such Act) (other than the applicable Party), directly or indirectly, of securities of such Party (or the
surviving company of such merger, consolidation or other such transaction or transactions, as applicable) representing fifty percent (50%) or more of the combined voting power of such Party’s (or such surviving company’s) then outstanding
securities; or (c) a sale or other disposition in one or a series of related transactions by a Party of all or substantially all of such Party’s assets. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

2. 

 “Commercially Reasonable Efforts” shall mean, with respect to the Development and
commercialization of Licensed Products by a Party, that level of efforts and resources which [ * ]. Commercially Reasonable Efforts shall be determined on a
market-by-market basis for each Licensed Product. 
 “Confidential
Information” shall mean, with respect to a Party (the “Receiving Party”), all information, which is disclosed by the other Party (the “Disclosing Party”) to the Receiving Party hereunder or to any of its
employees, consultants, legal or financial advisors, Affiliates, licensees or sublicensees (“Representatives”), except to the extent that such information, (a) as of the date of disclosure is demonstrably known to the Receiving
Party or its Representatives, as shown by written documentation, other than by virtue of a prior confidential disclosure to such Party or its Representatives by the Disclosing Party or its predecessors; (b) as of the date of disclosure is in,
or subsequently enters, the public domain, through no fault or omission of the Receiving Party or its predecessors; (c) is obtained by the Receiving Party or its Representatives from a Third Party having a lawful right to make such disclosure
free from any obligation of confidentiality or fiduciary duty to the Disclosing Party or its predecessors; or (d) is independently developed by or for the Receiving Party or its Representatives without reference to or reliance upon any
Confidential Information of the Disclosing Party or its predecessors as demonstrated by competent written records. 
 “Control” or
“Controlled” shall mean, with respect to any Patent Rights or Know-How, the possession by a Party of the ability to grant a license or sublicense of such Patent Rights or Know-How as provided for herein without violating the terms of any arrangement or agreements between such Party and any Third Party, unless otherwise provided for in this Agreement. 

“Development” and “Develop” shall mean, with respect to any Licensed Product, all activities relating to research and
development including without limitation, all pre-clinical and non-clinical research and development activities (including formulation and reformulation activities), all
human and veterinary clinical studies, all activities relating to developing the ability to manufacture any Licensed Product or any component thereof (including, without limitation, process development work), and all other activities relating to
seeking, obtaining and/or maintaining any Regulatory Approvals from any Regulatory Authority, including the publishing of certain data and other results as may be necessary in connection with the foregoing. 

“Dispute” shall have the meaning for such term set forth in Section 12.1. 

“Effective Date” shall have the meaning for such term set forth in the Recitals. 

“EMA” shall mean the European Medicines Agency or any successor agency thereto. 

“Expert” shall have the meaning for such term set forth in Section 12.5.1. 

“Field” shall mean the mitigation, prevention, treatment, control or diagnosis of any disorder, condition or disease that is caused by a
disorder of the central nervous system and/or the peripheral nervous system, including Alzheimer’s disease, Parkinson’s disease, Multiple sclerosis, Huntington’s disease, Amyotrophic lateral sclerosis and any other neuropsychiatric or
neurodegenerative diseases of the central nervous system and/or the peripheral nervous system. For avoidance of doubt, the Field specifically excludes the Vivimind Field as well as the mitigation, prevention, treatment, control or diagnosis of any
disorder, condition or diseases that are not caused by disorders of the central nervous system or the peripheral nervous system, and/or the disorders, conditions and diseases listed on Schedule C hereto. 

“First Commercial Sale” shall mean, on a country-by-country
and Licensed Product-by-Licensed Product basis, the first Sale of a Licensed Product by Alzheon or any of its Affiliates or permitted sublicensees to a Third Party in a
country for use in the Field after such Licensed 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

3. 

 
Product has been granted Regulatory Approval in such country. For the sake of clarity, transfers or dispositions of Licensed Product for charitable, promotional (including samples), pre-clinical, clinical or regulatory purposes shall not constitute “Sales” for purposes of this definition. 

“GAAP” shall mean the International Financial Reporting Standards and the official pronouncements issued by the International Accounting
Standards Board. 
 “ICC Rules” shall have the meaning for such term set forth in Section 12.4.2. 

“Improvements” shall have the meaning for such term set forth in Section 3.1.3. 

“Indemnitee” shall mean the Alzheon Indemnitee or the Licensor Indemnitee. 

“Indemnitor” shall have the meaning for such term set forth in Section 10.3. 

“Infringement” shall have the meaning for such term set forth in Section 7.5. 

“Insolvency Event” shall have the meaning for such term set forth in Section 11.4. 

“Inventory Sale Period” shall have the meaning for such term set forth in Section 11.6.3. 

“Italy Commercialization Agreement” shall have the meaning for such term set forth in Section 3.2.2(a). 

“Italy Net Sales” shall have the meaning for such term set forth in Section 4.2. 

“Know-How” shall mean and include any and all unpatented (whether or not patentable) proprietary
ideas, inventions, discoveries, Confidential Information, biologic materials, data, results, formulae, designs, specifications, scientific methods, business plans and methods, processes, formulations, techniques,
know-how, technical information (including, without limitation, structural and functional information), process information, pre-clinical information, clinical
information, and any and all proprietary biological, chemical, pharmacological, toxicological, pre-clinical, clinical, assay, control and manufacturing data and materials. 

“Laws” shall mean all provisions of all (a) constitutions, treaties, laws, statutes, codes, ordinances, orders, decrees, rules,
regulations and municipal by-laws, whether domestic, foreign or international, (b) judgments, orders, writs, injunctions, decisions, rulings, decrees and words of any governmental or regulatory body or
authority, and (c) all policies, voluntary restraints, practices and guidelines of any Regulatory Authority, in each case binding on or affecting the Party referred to in the context in which such word is used. 

“Letter Agreement” shall have the meaning for such term set forth in the Recitals. 

“Licensed Data” shall mean any and all in vitro, in vivo, pre-clinical and clinical data related to
the Licensed Products that is Controlled by the Licensor on the Effective Date or during the Term, including all such data that is Controlled by the Licensor pursuant to the Bellus License Agreement. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

4. 

 “Licensed Know-How” shall mean all Know-How Controlled by the Licensor on the Effective Date or during the Term that is necessary or useful for the Development, manufacture or commercialization of the Licensed Products, including the Licensed Data,
any Know-How that is solely and exclusively related to the Licensed Patent Rights and all Know-How that is Controlled by the Licensor pursuant to the Bellus License
Agreement. 
 “Licensed Patent Rights” shall mean (i) all Patents Rights Controlled by the Licensor on the Effective Date or during
the Term that are necessary for the Development, manufacture or commercialization of the Licensed Products, including all Patent Rights with respect to the patents and patent applications listed in Schedule A and Schedule B hereto and
all Patent Rights Controlled by the Licensor pursuant to the Bellus License Agreement and (ii) all Patent Rights in the Improvements Controlled by the Licensor during the Term. 

“Licensed Product” shall mean any product that contains 3-amino-1-propanesulfonic acid (“3-APS”) or any prodrug, analog, salt, free acid, free base, clathrate, solvate, hydrate, hemihydrate, anhydride,
ester, chelate, conformer, congener, crystal form, crystal habit, polymorph, amorphous solid, homolog, isomer, stereoisomer, enantiomer, racemate, isotopic or radiolabeled equivalent, metabolite or conjugates of
3-APS. 
 “Licensed Technology” shall mean collectively the Licensed Patent Rights and the Licensed
Know-How. 
 “Licensor” shall have the meaning for such term set forth in the Recitals. 

“Licensing Revenue” shall mean any consideration (including all upfront and milestone payments) paid by a Third Party to Alzheon, one of its
Affiliates or one of its or their sublicensees, in exchange for a grant to such Third Party of a sublicense or other right, license, privilege or immunity under or with respect to the Licensed Technology (including in relation to commercial sales),
provided that Licensing Revenue shall exclude (i) Royalties and (ii) any and all fees paid to Alzheon, one of its Affiliates or one of its or their sublicensees for services performed by Alzheon, one of its Affiliates or one of its
or their sublicensees for the Development of the Licensed Products, or any other similar or ancillary services which are provided by Alzheon, one of its Affiliates or one of its or their sublicensees following the date upon which Alzheon, any of its
Affiliates or any of its or their sublicensees first receives any revenue related to a Licensed Product. For greater certainty, consideration paid in transactions between or among Alzheon and its Affiliates shall be excluded from the computation of
the Licensing Revenue, but Licensing Revenue shall include consideration paid in transactions between or among Alzheon’s, its Affiliates or its or their sublicensees and Third Parties, but only to the extent that such consideration qualifies as
“Licensing Revenue” as defined in the immediately preceding sentence. Where (a) Licensing Revenue is payable to Alzheon, one of its Affiliates or one of its or their sublicensees other than in an arms-length transaction, (b) Licensing
Revenue is payable as one of a number of items without a separate itemized consideration; or (c) Licensing Revenue includes any non-cash element (including equity that is paid in exchange for a grant of a sublicense or other right, license,
privilege or immunity under or with respect to the Licensed Technology), the consideration payable as Licensing Revenue shall be deemed to be the Licensing Revenue that would otherwise have been payable by a Third Party in an arm’s length
transaction for the rights licensed at that time. 
 “Licensor Indemnitees” shall have the meaning for such term set forth in
Section 10.1. 
 “Net Sales” shall mean, with respect to a Licensed Product, the gross amount invoiced for sales of any Licensed
Product in the Territory directly or in arm’s length sales by Alzheon (and its authorized Affiliates) or permitted sublicensees to Third Parties, less the following deductions from such gross amounts which are actually incurred, allowed,
accrued or specifically allocated to such Licensed Product: credits, price adjustments or allowances for damaged products, returns or rejections of, and for uncollectible amounts on, previously sold Licensed Product; (b) normal and customary trade,
cash and quantity discounts, allowances and credits (other than price discounts granted at the time of invoicing which have already been included in the gross amount invoiced); (c) chargeback payments, repayments and rebates (or the equivalent
thereof) granted to or imposed by group purchasing organizations, managed health care organizations or federal, state/provincial, local and other governments, including any or all of their regulatory authorities, agencies, review boards or
tribunals, or trade customers; (d) any invoiced freight, postage, shipping, insurance and other transportation charges related to the distribution of such Licensed Product; (e) wholesaler and distributor administration fees; (f) sales, value-added
(to the extent not refundable in accordance with applicable Law), and excise taxes (including pharmaceutical excise taxes, such as those imposed by the United States Patient Protection and Affordable Care Act of 2010 (Pub. L. No. 111-48) and other
comparable Laws), tariffs and duties, and other taxes directly related to the sale (but not including taxes assessed against the income derived from such sale); (g) stocking allowances; and (h) any other payment which reduces gross revenue and is
permitted to be deducted in calculating revenue in accordance with GAAP. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

5. 

 In the case of any sale or other disposal for value, such as barter or counter-trade, of a Licensed Product, or
part thereof, other than in an arm’s length transaction exclusively for cash, Net Sales shall be calculated as above on the value of the non-cash consideration received or the fair market price (if higher) of such Licensed Product in the
country of sale or disposal, as determined in accordance with GAAP. 
 Notwithstanding the foregoing, Net Sales shall not be imputed to transfers of
Licensed Product for use in any clinical trial of a Licensed Product, for bona fide charitable purposes or for compassionate use, or for samples of Licensed Product, provided that Alzheon and its Affiliates receive no consideration from such
transfers of Licensed Products. 
 Notwithstanding the foregoing, in the event a Licensed Product is sold as a Combination Product, Net Sales shall be
calculated by multiplying the Net Sales of the Combination Product by the fraction A/(A+B), where A is the gross invoice price of the Licensed Product when sold separately in a country and B is the gross invoice price of the other active
ingredient(s) included in the Combination Product when sold separately in such country. In the event no such separate sales are made by Alzheon (or its authorized Affiliates) or its permitted sublicensees, Net Sales of the Combination Product shall
be calculated in a manner to be negotiated and agreed upon by the Parties, reasonably and in good faith, prior to any Sale of such Combination Product, which shall be based upon the respective cost of goods sold of the active ingredient(s) of such
Combination Product. For purposes of this definition, “Combination Product” means any product that comprises a Licensed Product sold in conjunction with another active component so as to be a combination product (whether packaged
together or in the same therapeutic formulation). 
 “Option” shall have the meaning for such term set forth in Section 3.2.2. 

“Option Exercise Deadline” shall have the meaning for such term set forth in Section 3.2.2. 

“Option Exercise Notice” shall have the meaning for such term set forth in Section 3.2.2. 

“Option Trigger Notice” shall have the meaning for such term set forth in Section 3.2.2. 

“Other Licensed Patent Rights” shall have the meaning for such term set forth in Section 7.1.2. 

“Parteq AA” shall have the meaning for such term set forth in Section 8.1.14. 

“Parteq Agreement” shall have the meaning for such term set forth in Section 8.1.14. 

“Parteq LA” shall have the meaning for such term set forth in Section 8.1.14. 

“Party” and “Parties” shall have the meaning for such term set forth in the Recitals. 

“Patent Rights” shall mean the rights and interests in and to (a) issued patents; (b) pending patent applications and any related
patent applications filed in the future claiming priority thereto, including all provisional applications, non-provisional applications, international (PCT) applications, substitutions, renewals, divisionals,
continuations, continued prosecution applications or continuations-in-part, and all patents granted thereon or issuing therefrom; (c) patents of addition, reissues,
re-examinations, extensions, confirmations, registrations, revalidations, revisions and restorations by existing or future extension or restoration mechanisms, including supplementary protection certificates
or the equivalent thereof, granted 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

6. 

 
with respect to any of the foregoing; (d) registration patents, inventor’s certificates, utility models or confirmation patents granted on or issuing from any of the foregoing;
(e) any form of government-issued right substantially similar to any of the foregoing, in each case with respect to clauses (a) through (e), in any country or patent examining or granting jurisdiction in the Territory. 

“Pending Claim” shall mean a bona fide pending claim in a patent application within the Licensed Patent Rights that (a) has not been
disclaimed, revoked, withdrawn or abandoned; (b) has not been unappealably cancelled or rejected by any administrative agency or other body of competent jurisdiction; (c) has not been declared unpatentable by any administrative agency,
under a decision of a court or other body of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal; or (d) has not been lost through an interference proceeding. Notwithstanding the foregoing, any patent
application within the Licensed Patent Rights listed in Schedule A that has been pending for more than [ * ] from [ * ] shall not be considered to contain any Pending Claims for purposes of this Agreement. 

“Person” shall mean an individual, a limited liability company, a joint venture, a corporation, a partnership, an association, a trust, a
division or an operating group of any of the foregoing or any other entity or organization. 
 “Regulatory Approval” shall mean any and all
approvals (including pricing and reimbursement approvals), product and establishment licenses, registrations or authorizations of any kind of any Regulatory Authority necessary for the development,
pre-clinical and/or human clinical testing, manufacture, quality testing, supply, use, storage, importation, export, transport, marketing and sale of a Licensed Product (or any component thereof) in any
country or other jurisdiction in the Territory. 
 “Regulatory Authorities” shall mean any applicable supranational, national, federal,
state, provincial or local regulatory agency, department, bureau or other governmental entity of any country or jurisdiction in the Territory, having responsibility in such country or jurisdiction for any regulatory approvals of any kind in such
country or jurisdiction, and any successor agency or authority thereto. 
 “Right of Reference” shall mean the authority to rely upon, and
otherwise use, an investigation for the purpose of obtaining a regulatory approval, including the ability to make available the underlying raw data from the investigation for audit by the applicable Regulatory Authority, if necessary. 

“Royalties” shall have the meaning for such term set forth in Section 4.1.1. 

“Royalty Term” shall mean, on a country-by-country and
Licensed Product-by-Licensed Product basis, the period of time commencing on the date of the First Commercial Sale of a Licensed Product in a country and ending on the
date on which there is no Pending Claim or Valid Claim covering the use, manufacture, sale, offer for sale or importation of such Licensed Product in such country. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

7. 

 “Sell”, “Sale”, “Sold” shall mean the sale, rent, lease,
license or other form of distribution of a Licensed Product, to an end-user, distributor, or any other Person, either directly or through a chain of distribution, for financial consideration, but excludes any
returns. 
 “Sued Party” shall have the meaning for such term set forth in Section 7.7.1. 

“Term” shall have the meaning for such term set forth in Section 11.1. 

“Territory” shall mean all countries and jurisdictions of the world. 

“Third Party” shall mean any Person other than Alzheon, the Licensor and their respective Affiliates. 

“Third Party Payments” shall have the meaning for such term set forth in Section 4.1.2. 

“TPC Agreement” shall have the meaning for such term set forth in Section 8.1.16. 

“Valid Claim” shall mean a claim in an issued, unexpired patent within the Licensed Patent Rights that (a) has not been finally
cancelled, withdrawn, abandoned or rejected by any administrative agency or other body of competent jurisdiction, (b) has not been revoked, held invalid, or declared unpatentable or unenforceable in a decision of a court or other body of
competent jurisdiction that is unappealable or unappealed within the time allowed for appeal, (c) has not been rendered unenforceable through disclaimer or otherwise, or (d) has not been lost through an interference proceeding. 

“Vivimind Field” shall mean the use of a product as a nutraceutical or dietary supplement but specifically excluding any pharmaceutical
classification. 
 “Vivimind Product” shall mean any “Licensed Product” as defined in the Vivimind License Agreement. 

“Vivimind License Agreement” shall mean that certain License Agreement by and between the Licensor and BHI Limited Partnership, of even date
herewith. 
  

	2.	 GRANT OF RIGHTS 

 

	2.1	 License to Alzheon. Subject to the terms and conditions of this Agreement, the Licensor hereby grants to
Alzheon a royalty-bearing, irrevocable (except as set forth herein), exclusive (even as to the Licensor) license or sublicense (as applicable) in the Territory, including the right to grant sublicenses solely in accordance with Section 2.3,
under the Licensed Technology to: (a) use, have used, Develop, have Developed, make, have made, modify, have modified, enhance, have enhanced, improve and have improved the Licensed Technology and the Licensed Products for the Field and
(b) use, have used, manufacture, have manufactured, market, sell, offer for sale, have sold, import, have imported, distribute and have distributed the Licensed Products in the Field in the Territory. Alzheon acknowledges and agrees that, with
respect to the Licensed Technology that is Controlled by the Licensor pursuant to the Bellus License Agreement, 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

8. 

	 	
the sublicense to Alzheon granted herein, and Alzheon’s obligations with regard thereto, shall at all times be subject to the applicable terms and conditions of the Bellus License Agreement.

  

	2.2	 Restriction to License. For avoidance of doubt, the Parties agree that (a) Alzheon is not granted
any rights hereunder to use, have used, Develop, have Developed, make, have made, modify, have modified, enhance, have enhanced, improve, have improved the Licensed Technology or the Licensed Products outside the Field, or to manufacture, have
manufactured, market, sell, offer for sale, have sold, import, have imported, distribute or have distributed the Licensed Products outside the Field and (b) the Licensor shall retain no rights to use, have used, Develop, have Developed, make,
have made, modify, have modified, enhance, have enhanced, improve, have improved the Licensed Technology or the Licensed Products for the Field, or to manufacture, have manufactured, market, sell, offer for sale, have sold, import, have imported,
distribute or have distributed the Licensed Products in the Field. 

  

	2.3	 Right to Sublicense. Alzheon shall have the right to grant sublicenses to all or any portion of its
rights under the license granted pursuant to Section 2.1. Any sublicense granted hereunder shall be in writing and contain terms not materially less protective of the Licensor’s rights than those contained herein. Alzheon shall remain
liable to the Licensor for any breaches of this Agreement that result from the acts or omissions of any sublicensee. Alzheon shall provide the Licensor with a copy of each sublicense granted by Alzheon pursuant to this Section 2.3,
provided that Alzheon may redact those portions of such sublicense that are not reasonably necessary for the Licensor to verify compliance with this Agreement. 

 

	2.4	 Right of Reference. The Licensor hereby grants to Alzheon and its Affiliates and sublicensees an
exclusive Right of Reference to, and a royalty-bearing, irrevocable (except as set forth herein), exclusive (even as to the Licensor) license or sublicense (as applicable) to access and use, the Licensed Data (and any regulatory submissions,
clinical dossiers and regulatory approvals that include such Licensed Data) for any and all purposes, other than developing, commercializing and/or seeking regulatory approval for the Vivimind Product in the Vivimind Field. The Licensor shall, at
Alzheon’s request, provide a signed statement in accordance with 21 C.F.R. 314.50(g)(3) (or any analogous Law outside the United States), or otherwise provide appropriate notification of such right to the applicable Regulatory Authority, to the
extent necessary for Alzheon and its Affiliates and sublicensees to exercise the Right of Reference granted hereunder. 

  

	2.5	 Rights in Bankruptcy. 

 

	 	2.5.1	 All rights and licenses now or hereafter granted by the Licensor to Alzheon under or pursuant to this
Agreement, including, for the avoidance of doubt, the licenses granted to Alzheon pursuant to Section 2. 1, are, for all purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined
in the Bankruptcy Code. Upon the occurrence of any Insolvency Event with respect to the Licensor, the Licensor agrees that Alzheon, as licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

9. 

	 	
and elections under the Bankruptcy Code. Further, each Party agrees and acknowledges that, notwithstanding anything to the contrary in this Agreement, all payments by Alzheon to the Licensor
hereunder, other than the Royalties, do not constitute royalties within the meaning of Section 365(n) of the Bankruptcy Code or relate to licenses of intellectual property hereunder. The Licensor shall, during the Term, create and maintain
current copies or, if not amenable to copying, detailed descriptions or other appropriate embodiments, to the extent feasible, of all Licensed Technology. The Licensor and Alzheon acknowledge and agree that “embodiments” of intellectual
property within the meaning of Section 365(n) include, without limitation, all physical embodiments of the Licensed Know-How. If (a) a case under the Bankruptcy Code is commenced by or against the
Licensor, (b) this Agreement is rejected as provided in the Bankruptcy Code and (c) Alzheon elects to retain its rights hereunder as provided in Section 365(n) of the Bankruptcy Code, the Licensor (in any capacity, including debtor-in-possession) and its successors and assigns (including a trustee) shall comply with the provisions of this Section 2.5.1. 

 

	 	(a)	 The Licensor shall provide to Alzheon all Licensed Technology (including all embodiments thereof) held by the
Licensor and such successors and assigns, or otherwise available to them, immediately upon Alzheon’s written request. Whenever the Licensor or any of its successors or assigns provides to Alzheon any of the Licensed Technology (or any
embodiment thereof) pursuant to this Section 2.5.1(a), Alzheon shall have the right to perform the Licensor’s obligations hereunder with respect to such Licensed Technology, but neither such provision nor such performance by Alzheon shall
release the Licensor from liability resulting from rejection of the license or the failure to perform such obligations. 

  

	 	(b)	 The Licensor shall not interfere with Alzheon’s rights under this Agreement, or any agreement supplemental
hereto, to the Licensed Technology (including any embodiments thereof), including any right to obtain such Licensed Technology (or such embodiments) from another entity, to the extent provided in Section 365(n) of the Bankruptcy Code.

  

	 	2.5.2	 All rights, powers and remedies of Alzheon provided herein are in addition to and not in substitution for any
and all other rights, powers and remedies now or hereafter existing at law or in equity (including the Bankruptcy Code) in the event of the commencement of a case under the Bankruptcy Code with respect to the Licensor. The Parties agree that they
intend the following rights to apply to the maximum extent permitted by law, and to be enforceable under Bankruptcy Code Section 365(n): 

  

	 	(a)	 the right of access to any intellectual property (including all embodiments thereof) of the Licensor, or any
Third Party with whom the Licensor contracts to perform an obligation of the Licensor under this Agreement, and, in the case of the Third Party, which is necessary for the manufacture, use, sale, offering for sale, import or export of Licensed
Products; and 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

10. 

	 	(b)	 the right to contract directly with any Third Party with whom the Licensor contracts to perform an obligation
of the Licensor under this Agreement to complete such contracted work. 

  

	2.6	 Initial Information Transfer. Within a reasonable period of time after the Effective Date (but in no
event later than [ * ] after the Effective Date), the Licensor shall make available or cause to be made available to Alzheon, in a mutually-agreed upon format, (a) the Licensed Data and any other material data included in the Licensed Know-How and (b) other information regarding the Licensed Technology that is [ * ]. During the Term, the Licensor shall transfer or make available or shall cause to be transferred or made available to Alzheon,
in a mutually agreed upon format, all new Licensed Know-How that comes into the Control of the Licensor within [ * ] after such Licensed Know-How comes into the
Licensor’s control. 

  

	3.	 DEVELOPMENT AND COMMERCIALIZATION OF LICENSED PRODUCTS 

 

	3.1	 Research and Development 

 

	 	3.1.1	 Alzheon Rights. The Licensor hereby sublicenses to Alzheon on the Effective Date all of its rights under
the Bellus License Agreement with respect to the Development of the Licensed Products in the Territory for the Field, and Alzheon acknowledges and agrees that all such rights, and Alzheon’s obligations with regard thereto, shall at all times be
subject to the applicable terms and conditions of the Bellus License Agreement. On and after the Effective Date, Alzheon shall have sole and exclusive control, authority and responsibility over the Development of the Licensed Products in the
Territory for the Field. 

  

	 	3.1.2	 Alzheon Diligence Obligations. In accordance with Section 2.3 of the Bellus License Agreement,
Alzheon shall fully satisfy, on behalf of the Licensor, the following obligations: 

  

	 	(a)	 during the Term, Alzheon shall use Commercially Reasonable Efforts to Develop and seek to commercialize at
least one Licensed Product in the Field in the Territory; 

  

	 	(b)	 Alzheon shall or shall cause one of its sublicensees to, dose the first healthy individual in any study of a
Licensed Product in the Field no later than the second (2nd) anniversary of the Effective Date; and 

  

	 	(c)	 Alzheon shall or shall cause one of its sublicensees to, dose the first patient in a clinical trial of a
Licensed Product in its respective Field no later than the third (3rd) anniversary of the Effective Date. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

11. 

	 	3.1.3	 Arising Intellectual Property. During the Term, all right, title and interest in and to any enhancement,
invention or discovery created, conceived, identified, or reduced to practice by Alzheon, any of its Affiliates or any sublicensee or by a Third Party on behalf of Alzheon that relies on or incorporates the Licensed Technology (an
“Improvement”) shall be assigned by Alzheon, or Alzheon shall cause such right, title and interest to be assigned by such Third Party, to the Licensor or its designee. The Parties acknowledge and agree that, pursuant to
Section 3.1.3 of the Bellus License Agreement, the Licensor is required to assign to Bellus all Improvements that rely on or incorporate any Licensed Technology that is Controlled by the Licensor pursuant to the Bellus License Agreement, but
such Improvements shall be Controlled by the Licensor pursuant to the Bellus License Agreement and sublicensed to Alzheon pursuant to Section 2.1 of this Agreement. 

 

	3.2	 Commercialization. 

 

	 	3.2.1	 Alzheon Rights. The Licensor hereby sublicenses to Alzheon on the Effective Date all of its rights under
the Bellus License Agreement with respect to the commercialization of the Licensed Products in the Territory for the Field, and Alzheon acknowledges and agrees that all such rights, and Alzheon’s obligations with regard thereto, shall at all
times be subject to the applicable terms and conditions of the Bellus License Agreement. Without limiting any rights of Alzheon herein, but subject to Section 3.2.2 and Article 7, on and after the Effective Date, Alzheon shall have sole and
exclusive control, authority and responsibility over all commercialization of Licensed Products in the Territory for the Field, including without limitation (a) all activities relating to manufacture and supply of all Licensed Products;
(b) all marketing, promotion, sales, distribution, import and export activities relating to any Licensed Product; and (c) all activities relating to any regulatory filings, registrations, applications and Regulatory Approvals relating to
any of the foregoing. 

  

	 	3.2.2	 Licensor Option to Commercialize Licensed Products in Italy. Notwithstanding any sublicense hereunder to
Alzheon by the Licensor, the Licensor shall have the exclusive right and option, in its sole discretion, to obtain exclusive rights to commercialize the Licensed Products in Italy on the terms and conditions set forth in this Section 3.2.2 (the
“Option”). If Alzheon intends to submit a marketing authorization application for any Licensed Product in the Field in Italy (whether to the EMA under the centralized EMA filing procedure or to the applicable Regulatory Authority in
Italy), Alzheon shall so notify the Licensor in writing and deliver a copy of such application to the Licensor (the “Option Trigger Notice”). The Licensor may exercise the Option with respect to the Licensed Products by delivering
written notice thereof (the “Option Exercise Notice”) to Alzheon no later than [ * ] after receiving the Option Trigger Notice (the “Option Exercise Deadline”). 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

12. 

	 	(a)	 If the Licensor delivers an Option Exercise Notice to Alzheon prior to the Option Exercise Deadline, then
Alzheon and the Licensor shall thereafter negotiate in good faith and attempt to agree upon a distribution and commercialization agreement in a mutually-agreed form, pursuant to which Alzheon shall grant the Licensor an exclusive, royalty-free,
fully paid-up license under the Licensed Technology and Improvements to commercialize the Licensed Products in the Field in Italy (the “Italy Commercialization Agreement”). The Italy
Commercialization Agreement shall contain commercially reasonable, arms-length terms and conditions customary to the distribution and commercialization of products similar to the Licensed Products and shall include the terms set forth on Exhibit
A attached hereto. [ * ]. 

  

	 	(b)	 If (i) the Licensor notifies Alzheon prior to the Option Exercise Deadline that it will not exercise the
Option or (ii) the Licensor fails to deliver an Option Exercise Notice to Alzheon on or prior to the Option Exercise Deadline, then Alzheon shall thereafter be free to commercialize the Licensed Products in the Field in Italy or to engage any
Third Party to undertake all or any portion of such commercialization activities and the Licensor shall thereafter have no further rights under this Section 3.2.2 or otherwise with respect to the commercialization of the Licensed Products in
Italy. 

  

	3.3	 Updates and Reports. During the Term, Alzheon shall keep the Licensor currently, and no less frequently
than [ * ], advised of its (and its Affiliates’ and sublicensees’) Development and commercialization activities with respect to the Licensed Products in the Field in the Territory. Without limiting the generality of the foregoing, Alzheon
shall provide to the Licensor: 

  

	 	3.3.1	 on a [ * ] basis, written materials summarizing the activities undertaken by or on behalf of Alzheon with
respect to the Development and commercialization of Licensed Products in the Field in the Territory, which materials shall include a reasonably detailed description of Alzheon’s efforts to achieve the diligence obligations set forth in
Section 3.1.2; 

  

	 	3.3.2	 prompt written notice of the obtaining of any Regulatory Approval in relation to any Licensed Product in the
Territory; 

  

	 	3.3.3	 prompt written notice of the occurrence of the First Commercial Sale of any Licensed Product in each country
and jurisdiction of the Territory; and 

  

	 	3.3.4	 prompt written notice upon the receipt of any Licensing Revenue. 

Alzheon shall be deemed to be in compliance with the requirements of this Section 3.3 so long as it provides the information and notices
described above in Sections 3.3.1 through 3.3.4, as well as any additional information requested by the Licensor that is [ * ]. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

13. 

	3.4	 Ownership of Submissions and Regulatory Approvals. Subject to Section 11.6, Alzheon shall own all
Regulatory Approvals for Licensed Products and any other submissions to any Regulatory Authority with respect to the Licensed Product in the Field in the Territory. 

 

	3.5	 Complaints; Recalls. During the Term, Alzheon shall be responsible for all matters relating to recalls
and medical inquiries relating to the Licensed Products in the Field in the Territory and shall do so in conformity with all applicable Laws. 

  

	3.6	 Adverse Drug Events. During the Term, Alzheon shall be responsible for all matters relating to the
reporting of adverse events concerning the Licensed Products in the Territory, including the creation and maintenance of global safety database(s) for adverse drug events, and shall do so in conformity with all applicable Laws.

  

	4.	 PAYMENTS AND ROYALTIES 

 

	4.1	 Royalty and Licensing Payments 

 

	 	4.1.1	 Royalty and Licensing Rates. In consideration of the grant of the license and the covenants and
representations hereunder, and subject to the other terms of this Agreement. Alzheon shall pay to the Licensor the aggregate of (i) during the Royalty Term for any Licensed Product in any country in the Territory, a royalty amount equal to [ *
] of Net Sales of such Licensed Product in such country (the “Royalties”) and (ii) during the Term, [ * ] of all Licensing Revenues. For the sake of clarity, if any Licensing Revenue is received by an Affiliate or a sublicensee
of Alzheon and such Affiliate or sublicensee pays a portion of such Licensing Revenue to Alzheon, Alzheon shall be required to pay the Licensor an amount equal to [ * ] of the total amount of Licensing Revenue received by such Affiliate or
sublicensee, regardless of the amount paid to Alzheon. For example, if an Affiliate or sublicensee of Alzheon receives total consideration of [ * ] in Licensing Revenue and pays Alzheon [ * ] of such Licensing Revenue pursuant to the terms of the
agreement between Alzheon and such Affiliate or sublicensee, then Alzheon would only be required to pay the Licensor [ * ] of Licensing Revenue received by such Affiliate or sublicensee. 

 

	 	4.1.2	 Payments under the Parteq Agreement and the TPC Agreement. In further consideration of the grant of the
license and the covenants and representations hereunder, and subject to the other terms of this Agreement, for the duration of the Term, Alzheon shall pay, in accordance with Section 8.3, any amounts due or that may become due by the Licensor
under the Parteq Agreement and the TPC Agreement as a result of the Development or commercialization of the Licensed Products by Alzheon or any of its sublicensees pursuant to this Agreement (the “Third Party Payments”). Any such
Third Party Payments shall be calculated in accordance with the relevant provisions of the Parteq Agreement or the TPC Agreement, as applicable. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

14. 

	4.2	 Third Party Licenses. If (a) Alzheon reasonably determines that it is [ * ] to obtain a license
from a Third Party under a Patent Right or other right to Develop, manufacture or commercialize a Licensed Product in the Field in the Territory and (b) the Licensor is commercializing the Licensed Products in Italy pursuant to the Italy
Commercialization Agreement, then Alzheon shall be responsible for payment of any amounts owed to such Third Party pursuant to such license and the Licensor shall reimburse Alzheon [ * ], provided that the [ * ]. 

 

	4.3	 Fully Paid-Up, Royalty Free Licenses. Following the expiration
of the Royalty Term for any Licensed Product in any country or other jurisdiction in the Territory, no further Royalties shall be payable in respect of Sales of such Licensed Product in such country or jurisdiction and, thereafter, the licenses
granted to Alzheon under this Agreement with respect to such Licensed Product in such country or jurisdiction shall automatically become fully paid-up, perpetual, irrevocable, royalty-free, non-exclusive licenses. 

  

	4.4	 Payment Terms 

 

	 	4.4.1	 Payment of Royalties and Licensing Revenues. Alzheon shall make any payments owed to the Licensor
hereunder in arrears, within [ * ] from the end of each calendar quarter in which such payment accrues. Each payment shall be accompanied by a report for each country in the Territory in which sales of Licensed Products occurred and/or with respect
to which Licensing Revenues were received in the calendar quarter covered by such statement, specifying: (a) the gross sales and Net Sales of each Licensed Product, if any, in such country’s currency; (b) the Royalties and Licensing
Revenue payable to the Licensor in Canadian dollars; and (c) the calculation of any Third Party Payments due with respect to such country. 

  

	 	4.4.2	 No Payment Due. For greater certainty, no Royalties shall be due to Licensor on Licensed Products which
were not Sold; i.e. Licensed Products that were returned or that were provided to an end-user without financial consideration, such as a sample, for example. 

 

	 	4.4.3	 Accounting. All payments hereunder shall be made to the Licensor in Italy in Canadian dollars.
Conversion of foreign currency to Canadian dollars, if applicable, shall be made at the conversion rate of the Bank of Canada on the last business day of the calendar quarter preceding the applicable calendar quarter. 

 

	 	4.4.4	 Interest. In the event that any payment due hereunder is not made when due, interest shall accrue at a
rate per annum equal to the lesser of [ * ], calculated on the number of days such payments are paid after the date such payments are due and compounded monthly. 

 

	 	4.4.5	 Taxes. All payments paid by Alzheon to the Licensor under this Agreement are exclusive of, and Alzheon
shall pay any sales, use, rental, custom, value added, consumption or other taxes, duties, levies, fees or charges that may be assessed in any jurisdiction resulting from or arising under this Agreement, except for

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

15. 

	 	
withholding taxes (to the extent applicable) which Alzheon shall be permitted to deduct from the applicable payments prior to making such payments to the Licensor. The Licensor shall collect and
remit such taxes, duties, levies, fees or charges as required under applicable Law. 

  

	4.5	 Records Retention; Review 

 

	 	4.5.1	 Payments. Alzheon and its Affiliates shall keep for at least [ * ] from the end of the calendar year to
which they pertain, complete and accurate books and records sufficient to support and confirm the calculation of gross invoiced sales, Net Sales, exchange rates, Royalties, Licensing Revenues and Third Party Payments under this Article 4.

  

	 	4.5.2	 Review. At the request of the Licensor or Bellus (the “Auditing Party”), upon at least
[ * ] prior written notice, and at the expense of the Auditing Party (except as otherwise provided herein), Alzheon shall permit an independent certified accounting firm selected by the Auditing Party, and reasonably acceptable to Alzheon, to
inspect (during regular business hours) the relevant records required to be maintained by Alzheon and its Affiliates under this Section 4.5. The independent certified accounting firm shall be entitled to review the then-preceding [ * ] of
records required to be maintained by Alzheon and its Affiliates under this Section 4.5 solely for purposes of verifying the accuracy of the reports submitted by Alzheon pursuant to Section 4.4.1 and the Licensing Revenues, Royalties and
Third Party Payments due hereunder. Such right may be exercised by the Auditing Parties only [ * ]. If any review reveals a deficiency in the calculation of payments resulting in an underpayment to the Licensor, Alzheon shall promptly pay the
Licensor the amount remaining to be paid, and if such underpayment is by [ * ] or more for [ * ], Alzheon shall pay the reasonable documented out-of-pocket expenses of
the review. Any independent certified accounting firm that performs an inspection pursuant to this Section 4.5.2 shall enter into a written confidentiality agreement with Alzheon on terms substantially similar to those set forth in Article 5 of
this Agreement. 

  

	 	4.5.3	 [ * ]. 

  

	5.	 TREATMENT OF CONFIDENTIAL INFORMATION 

 

	5.1	 Confidentiality Obligations. The Licensor and Alzheon each recognize that the other Party’s
Confidential Information constitutes highly valuable and proprietary confidential information. The Licensor and Alzheon each agree that it will keep confidential, and will cause its officers, employees, consultants, agents, Affiliates, licensees and
sublicensees to keep confidential, all Confidential Information of the other Party. Neither the Licensor nor Alzheon nor any of their respective officers, employees, consultants, agents, Affiliates, licensees or sublicensees shall use Confidential
Information of the other Party for any purpose whatsoever other than exercising any rights granted to it or reserved by it hereunder or performing its obligations hereunder. Without limiting the foregoing, each Party may disclose Confidential
Information of the other Party to the extent such 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

16. 

	 	
disclosure is reasonably necessary in (a) filing and prosecuting patent applications and maintaining patents which are filed in accordance with the provisions of this Agreement, or
(b) filing, prosecuting or defending litigation in accordance with the provisions of this Agreement, or (c) complying with applicable Laws, regulations, court orders or the requirements of any nationally recognized security exchange,
quotation system or over-the-counter market on which such Party has its securities listed or traded; provided, however, that if a Party is required to make
any such disclosure of the other Party’s Confidential Information, it will give reasonable advance written notice to the other Party of such disclosure requirement and will use reasonable efforts to assist such other Party in efforts to secure
confidential treatment of such information required to be disclosed. 

  

	5.2	 Limited Disclosure and Use. The Licensor and Alzheon each agree that it may disclose the other
Party’s Confidential Information to its Affiliates, licensees or sublicensees or any of its or their officers, employees, consultants or agents, provided that such disclosure shall (a) be made only if and to the extent reasonably
necessary to carry out its rights and obligations under this Agreement; (b) be limited to the maximum extent possible consistent with such rights and obligations; and (c) only be made to Persons who are bound by written confidentiality
obligations no less stringent than those set forth in this Article 5. The Licensor and Alzheon each further agree not to disclose or transfer the other Party’s Confidential Information to any Third Parties under any circumstance without the
prior written approval of the other Party (such approval not to be unreasonably withheld or delayed), except (i) as otherwise required by Law, (ii) to any prospective or actual investors, lenders or other financing sources, prospective or
actual acquirers, strategic partners, licensees or sublicensees who are bound by written confidentiality obligations no less stringent than those set forth in this Article 5 and (iii) as otherwise expressly permitted by this Agreement. Each
Party shall take such action, and shall cause its Affiliates, licensees or sublicensees to take such action, to preserve the confidentiality of each other’s Confidential Information as it would customarily take to preserve the confidentiality
of its own Confidential Information, and in no event, shall treat the other Party’s Confidential Information with less than reasonable care. Each Party, upon the request of the other Party, will return all the Confidential Information disclosed
or transferred to it by the other Party pursuant to this Agreement, including all copies and extracts of documents and all manifestations in whatever form, within [ * ] of the termination or expiration of this Agreement; provided,
however, that a Party may retain Confidential Information of the other Party relating to any license or right to use Licensed Technology which survives such termination, and one copy of all other Confidential Information may be retained in
inactive archives or by legal counsel solely for the purpose of establishing the contents thereof. 

  

	5.3	 Bankruptcy Procedures. All Confidential Information disclosed by one Party to the other, including all
intellectual property rights therein, shall remain the property of the Disclosing Party. In the event that a court or other legal or administrative tribunal, directly or through an appointed master, trustee or receiver, assumes partial or complete
control over the assets of either Party in connection with an Insolvency Event with respect to such Party, the bankrupt or insolvent Party shall promptly notify the court or other tribunal (a) that Confidential Information received from the
other Party under this 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

17. 

	 	
Agreement remains the property of the other Party and (b) of the confidentiality obligations under this Agreement. In addition, the bankrupt or insolvent Party shall, to the extent permitted
by Law, take all steps necessary or desirable to maintain the confidentiality of the other Party’s Confidential Information and to ensure that the court, other tribunal or appointee maintains such information in confidence in accordance with
the terms of this Agreement. 

  

	5.4	 Publicity. Subject to the terms hereof including, without limitation, Section 5.1, neither Party
may publicly disclose the existence or terms or any other matter of fact regarding this Agreement or the Bellus License Agreement without the prior written consent of the other Party; provided, however, that either Party may make such
a disclosure (a) to the extent required by Law or any regulation or requirements of any nationally recognized securities exchange, quotation system or
over-the-counter market on which such Party has its securities listed or traded; (b) to any prospective or actual investors, lenders or other financing sources,
prospective or actual acquirers, strategic partners, licensees or sublicensees who are bound by written confidentiality obligations no less stringent than those set forth in this Article 5; or (c) to persons or entities permitted disclosure of
Confidential Information pursuant to Section 5.2, but only to the extent and on the same terms and conditions as set forth in Section 5.2. In the event that a Party is required to disclose the existence or terms or any other matter of fact
regarding this Agreement in accordance with clause (a) of this Section 5.4, it will, to the extent permitted, provide reasonable advance written notice to the other Party of such disclosure requirement and will use reasonable efforts to
assist such other Party in efforts to secure confidential treatment of such information required to be disclosed. 

  

	5.5	 Use of Name. Neither Party shall employ or use the name of the other Party in any promotional materials
or advertising without the prior express written permission of the other Party as to each such use, except as otherwise previously set forth in a permitted disclosure pursuant to Section 5.4. 

 

	6.	 GOVERNANCE 

  

	6.1	 Alliance Managers. Promptly after the Effective Date, each Party shall designate a single representative
to manage all of the activities contemplated under this Agreement. Such designated representatives will be responsible for the day-to-day coordination of the activities
of the Parties with respect to the Licensed Products and will serve to facilitate communication between the Parties. Such designated representatives shall have experience and knowledge appropriate for managers with such project management
responsibilities. Each Party may change its designated representative from time to time upon notice to the other Party. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

18. 

	7.	 PROVISIONS CONCERNING THE FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS 

 

	7.1	 Patent Filing, Prosecution and Maintenance. 

 

	 	7.1.1	 Alzheon Responsibilities. Subject to the terms of Sections 7.2, 7.3 and 7.4, the Parties agree that
Alzheon shall prepare, file, prosecute, obtain and maintain, [ * ] and acting through patent attorneys or agents of its choice, all Licensed Patent Rights with respect to the patents and patent applications listed in Schedule B attached
hereto and all Patent Rights with respect to Improvements (the “BLU8499 Patent Rights”) throughout the Territory. The Licensor hereby assigns to Alzheon on the Effective Date all of its rights under the Bellus License Agreement with
respect to the preparation, filing, prosecuting, obtaining and maintenance of the BLU8499 Patent Rights (other than such rights that are sublicensed to Alzheon pursuant to Section 2.1), and Alzheon acknowledges and agrees that all such rights,
and Alzheon’s obligations with regard thereto, shall at all times be subject to the applicable terms and conditions of the Bellus License Agreement. In the event that Alzheon at any time or from time to time determines not to maintain any
BLU8499 Patent Right in any country or other jurisdiction in the Territory and such determination is not made for legitimate strategic reasons, it shall provide the Licensor with prior written notice of the same (given not less than [ * ] prior to
any applicable deadline with respect to maintaining any such right in the applicable Territory), in which case the Licensor may, by notice in writing, thereafter prepare, file, prosecute, obtain and maintain such BLU8499 Patent Right on its own
behalf and [ * ]. 

  

	 	7.1.2	 Licensor Responsibilities. Subject to the terms of Sections 7.2, 7.3 and 7.4, the Parties agree that, as
between the Parties, the Licensor shall prepare, file, prosecute, obtain and maintain, [ * ] and acting through patent attorneys or agents of its choice, all Licensed Patent Rights other than the BLU8499 Patent Rights, including the Patent Rights
with respect to the patents and patent applications listed on Schedule A (the “Other Licensed Patent Rights”), throughout the Territory; provided, however, that the Parties acknowledge and agree that Bellus
shall prepare, file, prosecute, obtain and maintain, [ * ] and acting through patent attorneys or agents of its choice, the Other Licensed Patent Rights that are Controlled by the Licensor pursuant to the Bellus License Agreement. In the event that
the Licensor or Bellus at any time or from time to time determines not to maintain any Other Licensed Patent Rights in any country or other jurisdiction in the Territory [ * ], the Licensor shall provide Alzheon with prior written notice of the same
(given not less than                [ * ] prior to any applicable deadline with respect to maintaining any such right in the applicable Territory), in which case Alzheon
may, by notice in writing to the Licensor, thereafter prepare, file, prosecute, obtain and maintain such Other Licensed Patent Rights on its own behalf and [ * ]. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

19. 

	7.2	 Expense Reimbursement. Alzheon shall reimburse to the Licensor [ * ] per year in connection with all
preparation, filing, prosecution and maintenance costs incurred by the Licensor and/or Bellus with respect to the Other Licensed Patent Rights resulting from Section 7.1.2. The aforementioned [ * ] shall be reduced to [ * ] for the calendar
years                [ * ] (inclusively) and further reduced to [ * ] for calendar years [ * ] and following (until    [ * ]). 

 

	7.3	 Cooperation. The Parties agree to cooperate in the preparation, filing, prosecution and maintenance of
all patent applications within the Licensed Patent Rights, including obtaining and executing necessary powers of attorney and assignments by the named inventors, providing relevant technical reports to the filing Party concerning the invention
disclosed in such patent application, obtaining execution of such other documents which shall be needed in the filing and prosecution of such patent applications, and, as requested, updating each other regarding the status of such patent
applications. Without limiting the generality of the foregoing, each Party shall keep the other Party reasonably informed of the status of the filing, prosecution and maintenance of each patent and patent application within the Licensed Patent
Rights, including [ * ]. 

  

	7.4	 Divisional and Continuation. The Parties agree that, upon Alzheon’s request, the Licensor shall
pursue additional patent claims under the Other Licensed Patent Rights through the filing of one or more divisionals or continuations in order to provide protection in respect of a product being developed by Alzheon. Alzheon shall promptly (and in
any event within [ * ] of presentation of an invoice therefor by the Licensor) pay [ * ] incurred by the Licensor in connection with such request (including, without limitation, [ * ]). Alzheon may direct the drafting of such divisionals and
continuations and review and comment on such filings, provided that, subject to Section 7.1.2, Alzheon shall have final decision making authority in all matters relating to the drafting, reviewing and approving of filings made in
relation to such divisionals and continuations. [ * ]. For avoidance of doubt, any preparation, filing, prosecution, obtaining and maintaining obligations with respect to any divisional and continuation related to the BLU8499 Patent Rights shall be
subject to the provisions of Section 7.1.1. 

  

	7.5	 Notice of Infringement. If, during the Term, either Party learns of any actual, alleged or threatened
infringement by a Third Party of any Licensed Patent Rights in the Territory (an “Infringement”), such Party shall promptly notify the other Party and shall provide such other Party with available evidence of such Infringement.

  

	7.6	 Infringement of Patent Rights. As between the Parties, Alzheon shall have the first right (but not the
obligation), at Alzheon’s expense and with legal counsel of its own choice, to bring suit or take other appropriate legal action (an “Action”) against any Infringement. The Licensor hereby assigns to Alzheon on the Effective
Date all of its rights under the Bellus License Agreement to take Action against any Infringement, and Alzheon acknowledges and agrees that all such rights, and Alzheon’s obligations with regard thereto, shall at all times be subject to the
applicable terms and conditions of the Bellus License Agreement. Licensor shall have the right, at its own expense, to participate in any such Action by Alzheon using counsel of Licensor’s own choice; provided, however,

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

20. 

	 	
that under no circumstances shall the foregoing affect the right of Alzheon to bring an Action against any Infringement. [ * ]. Under no circumstances shall Alzheon be entitled to settle any
Action in the Territory in respect of Licensed Patent Rights in any way that would                [ * ] without the prior written consent of the Licensor, which consent
shall not be unreasonably withheld or delayed. Any damages, monetary awards or other amounts recovered, whether by judgment or settlement, pursuant to any Action taken under this Section 7.6, in respect of the Territory, shall be applied as
follows: 

  

	 	(a)	 [ * ]; and 

  

	 	(b)	 [ * ]. 

If a Party brings any Action under this Section 7.6, the other Party agrees to be joined as party plaintiff if necessary to prosecute such
Action, and to give the Party bringing such Action reasonable assistance and authority to file and prosecute the suit; provided, however, that neither Party shall be required to [ * ]. 

 

	7.7	 Third Party Claims. 

 

	 	7.7.1	 If the Development or commercialization of a Licensed Product is alleged by a Third Party to infringe a Third
Party Patent Right or misappropriate Third Party Know-How, the Party that becomes aware of such allegation shall promptly notify the other Party and shall provide such other Party with a reasonably detailed
description of such claim. If a Third Party sues a Party (the “Sued Party”) alleging that the Development or commercialization of a Licensed Product by or on behalf of the Sued Party infringes such Third Party’s Patent Right(s)
or misappropriates such Third Party’s Know-How, then the Sued Party shall have the sole right (but not the obligation) to defend such suit. At the Sued Party’s request and cost, the other Party shall
reasonably assist the Sued Party in the defense of such Third Party suit and shall join such suit if deemed a necessary party. If the other Party does not join such Third Party suit, then the Sued Party shall report the status of such Third Party
suit to the other Party on a quarterly basis prior to and during the pendency of such Third Party suit. If Alzheon is the Sued Party, then Alzheon shall not settle such Third Party suit in any way that would [ * ] without the prior written consent
of the Licensor, as applicable, which consent shall not be unreasonably withheld or delayed. If the Licensor is the Sued Party, then the Licensor shall not settle such Third Party suit in any way that would [ * ] without the prior written consent of
Alzheon, which consent shall not be unreasonably withheld or delayed. Subject to the Parties’ respective indemnification obligations under Article 10, all litigation expenses associated with a Third Party suit (including settlement costs,
royalties paid in settlement of such suit and the payment of damages to the Third Party) shall be [ * ]. In the event that a Sued Party desires to settle a Third Party suit but such settlement would [ * ], then such other Party shall be,
notwithstanding the foregoing, [ * ]. For avoidance of doubt, such other Party shall be required to [ * ]. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

21. 

	 	7.7.2	 The Licensor hereby assigns to Alzheon on the Effective Date all of the Licensor’s rights under
Section 7.7 of the Bellus License Agreement with respect to any Third Party suits brought against Bellus alleging that the Development or commercialization of a Licensed Product by or on behalf of Bellus infringes a Third Party Patent Right or
misappropriates Third Party Know-How and such Licensed Product is being Developed and/or commercialized by Alzheon pursuant to this Agreement. Alzheon acknowledges and agrees that all such rights, and
Alzheon’s obligations with regard thereto, shall at all times be subject to the applicable terms and conditions of the Bellus License Agreement. 

  

	7.8	 Covenant Not to Take Action Adverse to Licensed Technology. Alzheon hereby covenants and agrees (and,
with respect to its Affiliates, licensees and sublicensees, represents and warrants) that neither it nor any of its Affiliates, licensees or sublicensees shall institute or participate in, or assist any Third Party to institute or participate in,
formal proceedings against, or otherwise take any action adverse to, the Licensor’s or any of its Affiliates’, licensees’ or sublicensees’ rights or asserted rights in respect of the Licensed Technology, including the Licensed
Patent Rights, including without limitation through any interference or similar proceeding, or in connection with any challenge to the ownership, validity or enforceability of the Licensed Technology, including the Licensed Patent Rights or any
claims thereof. 

  

	8.	 REPRESENTATIONS, WARRANTIES AND COVENANTS 

 

	8.1	 Licensor Representations. The Licensor represents and warrants to Alzheon that, as of the Effective
Date: 

  

	 	8.1.1	 it is a corporation or entity duly organized and validly existing under the Laws of the state or other
jurisdiction of its incorporation or formation; 

  

	 	8.1.2	 the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have
been duly authorized by all appropriate Licensor corporate actions; 

  

	 	8.1.3	 this Agreement is a legal and valid obligation binding upon the Licensor and enforceable in accordance with its
terms, and the execution, delivery and performance of this Agreement by the Parties does not conflict with any agreement, instrument or understanding to which the Licensor is a party of or by which it is bound; 

 

	 	8.1.4	 it has the power and authority to perform its obligations hereunder; 

 

	 	8.1.5	 it has the full right, power and authority to grant all of the rights, title and interests in the licenses
granted to Alzheon hereunder; 

  

	 	8.1.6	 the Licensor is the sole owner of the Licensed Technology or Controls the Licensed Technology (i.e., has
sufficient rights to grant to Alzheon the licenses and sublicenses contemplated by this Agreement); 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

22. 

	 	8.1.7	 the Licensor has not received any written notice or threat of any material suit, legal claim, action,
proceeding (other than patent oppositions) or investigation against the Licensor or any of its Affiliates that relates to any Licensed Product; 

  

	 	8.1.8	 the Licensor has not received any written notice threatening any orders, injunctions or decrees of any
Regulatory Authority or other governmental body applicable to any of the Licensed Products; 

  

	 	8.1.9	 the Licensor is not actually aware of, nor has Licensor received any written notice of, any allegations or
claims that the Licensed Technology infringes or misappropriates any intellectual property right of any Third Party; 

  

	 	8.1.10	 none of the Licensed Patent Rights have been adjudged invalid or unenforceable in whole or in part, other than
abandoned patents; 

  

	 	8.1.11	 the Licensor has not received any written notice of any suit, claim, action or proceeding challenging or
seeking to deny or restrict, directly or indirectly, the rights of the Licensor or any of its Affiliates in any of the Licensed Technology; 

  

	 	8.1.12	 to the Licensor’s knowledge, no Third Party is infringing or misappropriating the Licensed Technology;

  

	 	8.1.13	 except as disclosed by the Licensor to Alzheon prior to the Effective Date, none of the following events have
occurred with respect to any Licensed Product: (a) any material failure to comply with any regulatory requirement applicable to the conduct of a clinical trial involving the Licensed Product, (b) any material failure to comply with the
protocol or applicable ethical standards for any clinical trial involving the Licensed Product; (c) any unexpected adverse drug reaction occurring during any clinical trial involving the Licensed Product that the Licensor suspected was
drug-related; or (d) any serious adverse drug event concerning the Licensed Product; 

  

	 	8.1.14	 the Licensor has provided Alzheon with a complete copy of the License Agreement dated January 1, 1999
between Parteq Research and Development Innovations and Neurochem Inc., including all amendments and supplements thereto (the “Parteq LA”), and the Assignment Agreement dated February 1, 2006 between Parteq Research and
Development Innovations and Neurochem Inc., including all amendments and supplements thereto (the “Parteq AA” and collectively with the Parteq LA, the “Parteq Agreement”); 

 

	 	8.1.15	 the Parteq LA was terminated, replaced and superseded in all respects by the Parteq AA; 

 

	 	8.1.16	 the Licensor has provided Alzheon with a complete copy of the Contribution Agreement dated November 17,
1999 between Her Majesty the Queen in Right of Canada and Neurochem Inc., related to TPC Project No: 720-460609, including all amendments and supplements thereto (the “TPC Agreement”);

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

23. 

	 	8.1.17	 each of the Parteq AA and TPC Agreement are in full force and effect, and has not been modified or amended
except as set forth in the amendments and supplements provided to Alzheon prior to the Effective Date, and no party to the Parteq AA or the TPC Agreement is in default with respect to any material obligation thereunder; 

 

	 	8.1.18	 [ * ]; 

  

	 	8.1.19	 the Licensor has provided Alzheon with a complete copy of the Vivimind License Agreement; and

  

	 	8.1.20	 the Licensor has provided Alzheon with a complete copy of the Bellus License Agreement. 

 

	8.2	 Alzheon Representations. Alzheon represents and warrants to the Licensor that, as of the Effective Date:

  

	 	8.2.1	 it is a corporation or entity duly organized and validly existing under the Laws of the state or other
jurisdiction of its incorporation or formation; 

  

	 	8.2.2	 the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have
been duly authorized by all appropriate corporate actions of Alzheon; 

  

	 	8.2.3	 this Agreement is a legal and valid obligation binding upon Alzheon and enforceable in accordance with its
terms, and the execution, delivery and performance of this Agreement by the Parties does not conflict with any agreement, instrument or understanding to which Alzheon is a party of or by which it is bound; 

 

	 	8.2.4	 it has the power and authority to perform its obligations hereunder; and 

 

	 	8.2.5	 to Alzheon’s knowledge, no Third Party is infringing or misappropriating the Licensed Technology.

  

	8.3	 Licensor Covenants. 

 

	 	8.3.1	 The Licensor shall not execute or otherwise permit any amendment or modification of, or waiver of any provision
of, the Bellus License Agreement without the prior written consent of Alzheon. The Licensor shall take all actions reasonably necessary to enforce and maintain its rights under the Bellus License Agreement. The Licensor shall not make any election
or exercise any right or option (or omit to take any action) which would terminate or relinquish in whole or in part any right under the Bellus License Agreement. The Licensor shall comply with all of its obligations under the Bellus License
Agreement, including by paying all amounts due to Bellus thereunder. The Licensor shall take such actions as shall be necessary to keep in full force and effect the Bellus License 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

24. 

	 	
Agreement. The Licensor shall give prompt notice to Alzheon, together with a detailed summary of outstanding issues if Alzheon so requests, of any notice received from or given to Bellus of any
actual or alleged defaults, breaches, violations, proposed amendments or proposed modifications of, or any proposed waivers under, the Bellus License Agreement. In the event that the Licensor receives any such notice from Bellus regarding an actual
or alleged default, breach or violation by the Licensor, the Licensor shall promptly notify Alzheon, and [ * ] cure such default, breach or violation or otherwise proceed. 

 

	 	8.3.2	 The Licensor shall not license, sell, assign or otherwise transfer to any Person (including any Affiliate of
the Licensor) any Licensed Technology, or assign or otherwise transfer the Bellus License Agreement or any of its rights or obligations thereunder to any Person (including any Affiliate of the Licensor) (or agree to do any of the foregoing) except
to the extent permitted by, and in compliance with, Section 13.7. The Licensor shall not incur or permit to exist (and shall cause each of its Affiliates not to incur or permit to exist), with respect to any Licensed Technology, any lien,
encumbrance, charge, security interest, mortgage, liability, grant of license to Third Parties or other restriction (including in connection with any indebtedness). 

 

	 	8.3.3	 The Licensor shall not, without the prior written consent of Alzheon (which consent shall not be unreasonably
withheld or delayed), amend the Vivimind License Agreement in a manner [ * ]. The Licensor shall notify Alzheon promptly following any termination of the Vivimind License Agreement. 

 

	 	8.3.4	 In the event that the Licensor receives notice from Bellus that it intends to amend the Parteq Agreement or the
TPC Agreement, the Licensor shall promptly notify Alzheon, and [ * ]. 

  

	 	8.3.5	 Neither the Licensor nor any of its Affiliates shall conduct, or assist, authorize or enable any Third Parties
to conduct, any development of any Vivimind Product in the Vivimind Field other than development of products containing a Vivimind Product or a salt thereof in combination with another nutraceutical or dietary supplement for the Vivimind Field.

  

	 	8.3.6	 Neither the Licensor nor any of its Affiliates shall seek or obtain, or enable any Third Parties to seek or
obtain, regulatory approval of any Vivimind Product outside of the Vivimind Field. The Licensor shall, and shall cause its Affiliates and sublicensees, to provide Alzheon with an opportunity to review and comment on any application for regulatory
approval of any Vivimind Product for the Vivimind Field at least [ * ] prior to submitting such application to the relevant Regulatory Authority and to [ * ]. 

 

	 	8.3.7	 The Licensor shall perform, and shall cause its Affiliates and sublicensees to perform, all activities with
respect to the commercialization of the Vivimind Product in accordance with applicable Laws. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

25. 

	 	8.3.8	 The Licensor shall keep Alzheon currently, and no less frequently than [ * ], advised of its (and its
Affiliates’ and sublicensees’) development and commercialization activities with respect to the Vivimind Products in the Vivimind Field in the Territory. Without limiting the generality of the foregoing, the Licensor shall provide to
Alzheon: 

  

	 	(a)	 on a [ * ] basis, written materials summarizing the activities undertaken by or on behalf of the Licensor with
respect to the development and commercialization of Vivimind Products in the Vivimind Field in the Territory; 

  

	 	(b)	 prompt written notice of the obtaining of any regulatory approval in relation to any Vivimind Product in the
Territory; and 

  

	 	(c)	 prompt written notice of the occurrence of the sale of any Vivimind Product in the Vivimind Field in each
country and jurisdiction of the Territory. 

  

	 	8.3.9	 The Licensor shall promptly report to Alzheon any negative health effects associated with the use of any
Vivimind Product in the Vivimind Field of which the Licensor becomes aware. Upon Alzheon’s request, the Parties shall meet and discuss the appropriate actions to be taken in response to such negative health effects, including whether the
Vivimind Product should be recalled or withdrawn from the market, and the Licensor shall reasonably consider any suggestions or recommendations made by Alzheon. 

 

	 	8.3.10	 In the event that [ * ] and [ * ], then the Option granted to the Licensor under Section 3.2.2 or, if the
Option has been exercised and the Parties have executed the Italy Commercialization Agreement, the Italy Commercialization Agreement shall terminate automatically upon the expiration of such [ * ] period without any further action by Alzheon.

  

	8.4	 Alzheon Covenants. In accordance with Section 4.1.2, Alzheon shall assume any and all of the
payment and notice obligations set forth in the Parteq Agreement and the TPC Agreement with respect to the Third Party Payments. Licensor shall have the right from time to time (i) to cause Alzheon to direct any Third Party Payment required
pursuant to the Parteq Agreement or the TPC Agreement to be paid to the Licensor, which the Licensor shall then pay to the beneficiary thereof on its own behalf under the terms of said agreements or (ii) to cause Alzheon to direct any Third
Party Payment required pursuant to the Parteq Agreement or the TPC Agreement directly to the beneficiary thereof under the terms of said agreements. 

  

	8.5	 No Other Warranties. 

 

	 	8.5.1	 Except as expressly set forth in Section 8.1 above, nothing in this Agreement is or shall be construed as
a warranty or representation by the Licensor: (a) as to the ownership, validity or scope of the Licensed Technology, including the Licensed 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

26. 

	 	
Patent Rights and Licensed Know-How hereunder; or (b) that anything used, Developed, modified, enhanced, improved, manufactured, sold, offered for
sale, distributed or otherwise disposed of under any license granted pursuant to this Agreement is or will be free from infringement or misappropriation of patents, trademarks, copyrights and other rights of Third Parties. 

 

	 	8.5.2	 EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 8, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY
WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THE LICENSOR EXPRESSLY DISCLAIMS, TO THE FULLEST EXTENT PERMITTED BY LAW, ALL OTHER EXPRESS OR IMPLIED WARRANTIES, INCLUDING THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,
SATISFACTORY QUALITY AND NON-INFRINGEMENT. IN PARTICULAR, EACH PARTY ACKNOWLEDGES THAT THE RIGHTS GRANTED TO SUCH PARTY HEREIN ARE PROVIDED “AS IS, WHERE IS”. 

 

	9.	 INSURANCE 

  

	9.1	 During the Term, each Party shall carry and maintain at its expense, general comprehensive all risk insurance
and product liability insurance, in an amount not less than [ * ] per occurrence. All such insurance shall (a) be issued by insurers of recognized responsibility and who are reasonably acceptable by the other Party, (b) [ * ], and
(c) contain a specific clause whereby the other Party shall be notified by the insurer at least [ * ] before any cancellation or termination of any such insurance and a certificate of insurance evidencing same shall be delivered to the other
Party prior to any payment being made by the other Party hereunder. Notwithstanding the foregoing, Alzheon shall not be obliged to carry product liability insurance until it commences testing of any Licensed Product in humans. 

 

	9.2	 Neither the failure of a Party to comply with any or all of the insurance provisions of this Agreement nor the
failure to secure endorsements on the policies as may be necessary to carry out the terms and provisions of this Agreement shall be construed to limit or relieve such Party of any of its obligations under this Agreement including, without
limitation, those set out in this Article 9. 

  

	10.	 INDEMNIFICATION AND LIMITATION OF LIABILITY 

 

	10.1	 Alzheon Indemnity. Alzheon shall indemnify, defend and hold harmless the Licensor, its Affiliates and
their respective successors, heirs and assigns (the “Licensor Indemnitees”) from and against any liability, damage, loss or expense (including reasonable attorneys’ fees and expenses of litigation) incurred by or imposed upon
such the Licensor Indemnitees, or any of them, in connection with any Third Party claims, suits, actions, demands or judgments, including, without limitation, personal injury and product liability matters, to the extent arising out of (a) any
actions or omissions, or alleged actions or omissions, of Alzheon and its Affiliates in connection with the use, 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

27. 

	 	
Development, making, modification, enhancement or improvement of the Licensed Technology or the Licensed Products, or the use, manufacture, marketing, Sale, offering for Sale, importation or
distribution of the Licensed Products, including any claims that any such actions or omissions, or alleged actions or omissions, infringe or misappropriate any Third Party intellectual property rights; (b) any breach or alleged breach of a
representation or warranty of Alzheon set forth herein; (c) any breach or alleged breach of this Agreement by Alzheon or, with respect to any Affiliate of Alzheon, any act or omission that would constitute a breach of this Agreement were such
act or omission Alzheon’s own; or (d) the gross negligence or willful misconduct on the part of any Alzheon Indemnitee, except in each case to the extent caused by the gross negligence or willful misconduct of any Licensor Indemnitee
(including the Licensor) or by breach of this Agreement by the Licensor. 

  

	10.2	 Licensor Indemnity. The Licensor shall indemnify, defend and hold harmless Alzheon, its Affiliates and
their respective successors, heirs and assigns (the “Alzheon Indemnitees”) from and against any liability, damage, loss or expense (including reasonable attorneys’ fees and expenses of litigation) incurred by or imposed upon
such Alzheon Indemnitees, or any of them, in connection with any Third Party claims, suits, actions, demands or judgments, including, without limitation, personal injury and product liability matters, to the extent arising out of (a) any
actions or omissions, or alleged actions or omissions, of the Licensor, or its Affiliates, licensees or sublicensees, in connection with the use, development, making, modification, enhancement or improvement of the Licensed Technology or the
Licensed Products outside the Field or the Vivimind Products for the Vivimind Field, or the use, manufacture, marketing, Sale, offering for Sale, importation or distribution of the Licensed Products outside the Field or the Vivimind Products in the
Vivimind Field, including any claims that any such actions or omissions, or alleged actions or omissions, infringe or misappropriate any Third Party intellectual property rights; (b) any breach or alleged breach of a representation or warranty
of the Licensor set forth herein; (c) any breach or alleged breach of this Agreement by the Licensor or, with respect to any Affiliate of the Licensor, any act or omission that would constitute a breach of this Agreement were such act or
omission the Licensor’s own; or (d) the gross negligence or willful misconduct on the part of any Licensor Indemnitee, except in each case to the extent caused by the gross negligence or willful misconduct of any Alzheon Indemnitee
(including Alzheon) or by breach of this Agreement by Alzheon. 

  

	10.3	 Indemnification Procedures. In the event that any Indemnitee is seeking indemnification under
Section 10.1 or 10.2 above from a Party (the “Indemnitor”), the Indemnitee shall notify the Indemnitor of such claim with respect to such Indemnitee as soon as reasonably practicable after the Indemnitee receives notice of the
claim. The Indemnitor (on behalf of itself and such Indemnitee) shall, at its sole cost and expense, have full control of and authority over the defense of the claim (including the right to settle the claim) and the other Party and the Indemnitee
shall, at their own expense, cooperate as requested by the Indemnitor in the defense of the claim; provided, however, that the Indemnitee shall have the right to participate in (but not control) and be represented in any suit or action by
independent counsel at its own expense and provided, further, that the Indemnitor may not settle such claim without the Indemnitee’s prior written consent, which shall not be unreasonably withheld or delayed, to the extent that
such settlement materially affects the Indemnitee’s rights or obligations hereunder. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

28. 

	10.4	 Consequential Damages. EXCEPT WITH RESPECT TO ANY BREACH OF ARTICLE 5 OR INDEMNIFICATION OBLIGATIONS
UNDER ARTICLE 10, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL OR PUNITIVE DAMAGES (INCLUDING, BUT NOT LIMITED TO, DAMAGES FOR LOSS OF PROFITS, FOR BUSINESS INTERRUPTION, FOR FAILURE TO MEET ANY DUTY
OF GOOD FAITH OR OF REASONABLE CARE OR FOR NEGLIGENCE) ARISING OUT OF OR IN ANY WAY RELATED TO THE USE OF OR INABILITY TO USE THE LICENSED TECHNOLOGY OR OTHERWISE UNDER OR IN CONNECTION WITH ANY PROVISION OF THIS AGREEMENT EVEN IF ANY REPRESENTATIVE
OF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY THEREOF. 

  

	10.5	 Maximum Extent. THE TERMS OF THIS ARTICLE 10 SHALL APPLY TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE
LAW, EVEN IF THIS AGREEMENT OR ANY REMEDY FAILS ITS ESSENTIAL PURPOSE. 

  

	11.	 TERM AND TERMINATION 

 

	11.1	 Term; Expiration. The term of this Agreement shall commence on the Effective Date and, unless earlier
terminated under this Article 11, shall continue in full force and effect until the expiration of the last-to-expire Royalty Term (the “Term”).

  

	11.2	 Termination for Breach of Payment. This Agreement and the rights granted herein may be terminated by the
Licensor upon any breach of any payment obligation hereunder by Alzheon, effective [ * ] after giving written notice to Alzheon of such termination. If such default or breach is cured within the foregoing [ * ], the notice shall be deemed
automatically withdrawn and of no effect. 

  

	11.3	 Remedies for Other Breach. 

 

	 	11.3.1	 Subject to Sections 11.2 and 11.4, this Agreement and the rights granted herein may be terminated by either
Party upon any material breach of this Agreement by the other Party, effective [ * ] after giving written notice to the breaching Party of such termination. If such default or breach is cured within the foregoing [ * ] period, the notice shall be
deemed automatically withdrawn and of no effect. Notwithstanding the foregoing, if a Party is alleged to be in material breach and disputes such allegation through the dispute resolution procedures set forth in this Agreement, then the other
Party’s right to terminate this Agreement shall be tolled for so long as such dispute resolution procedures are being pursued in good faith and, if it is finally and conclusively determined that the Party is in material breach, then prior to
any termination becoming effective or any remedies being enforced, the breaching Party shall have the right to cure such material breach after such determination within a [ * ] cure period. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

29. 

	 	11.3.2	 If the Licensor materially breaches this Agreement, then Alzheon may, in lieu of exercising its right to
terminate pursuant to Section 11.3.1, elect to continue this Agreement and terminate the Option granted to the Licensor under Section 3.2.2 or, if the Option has been exercised and the Parties have executed the Italy Commercialization
Agreement, the Italy Commercialization Agreement. Alzheon shall notify the Licensor of such election in writing prior to the expiration of the [ * ] cure period under Section 11.3.1 and the termination of the Option or Italy Commercialization
Agreement, as applicable, shall take effect automatically if the Licensor’s breach or default is not cured within such [ * ] cure period. 

  

	11.4	 Termination for Bankruptcy. This Agreement may be terminated by written notice by either Party at any
time during the Term if the other Party shall file in any court or agency, pursuant to any bankruptcy and/or insolvency statute or regulation of any state, province or country, a petition in bankruptcy or insolvency or for reorganization or for an
arrangement or for the appointment of a receiver or trustee of that Party or of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party shall be served with an involuntary
petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within [ * ] after the filing thereof, or if the other Party shall propose or be a Party to any dissolution or liquidation, or if the other Party shall
make an assignment for the benefit of its creditors (each, an “Insolvency Event”). 

  

	11.5	 Alzheon Right of Termination. This Agreement may be terminated in its entirety at any time by Alzheon
for any reason, effective upon at least [ * ] prior written notice to the Licensor. 

  

	11.6	 Effects of Termination. 

 

	 	11.6.1	 Termination by the Licensor for any Reason or by Alzheon without Cause. 

 

	 	(a)	 Upon any termination of this Agreement by the Licensor hereunder or any termination of this Agreement by
Alzheon pursuant to Section 11.5, as of the effective date of such termination, all licenses and sublicenses granted by the Licensor to Alzheon hereunder (other than the licenses and sublicenses granted pursuant to Section 4.3) and each
sublicense granted by Alzheon and its Affiliates hereunder shall terminate immediately and automatically unless [ * ]. Alzheon shall immediately assign and transfer to the Licensor, [ * ], all of Alzheon’s right, title and interest in and to
all Regulatory Approvals and other submissions to Regulatory Authorities with respect to the Licensed Products in the Territory. Alzheon shall immediately transfer to the Licensor all the Confidential Information disclosed, transferred to it, or
generated by or on behalf of the Licensor in the context of this Agreement, including all copies and extracts of documents and all manifestations in whatever form, and all other data, if any, regarding clinical data, materials and information
(including, without limitation, all sales and marketing materials) in the possession of Alzheon or one of its Affiliates relating to the Licensed Products or the Licensed Technology. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

30. 

	 	(b)	 The rights and obligations of the Parties under Section 7.8 shall survive the termination of this
Agreement by the Licensor pursuant to Section 11.2 or 11.4. 

  

	 	11.6.2	 Termination by Alzheon for Cause. 

 

	 	(a)	 Upon any termination of this Agreement by Alzheon pursuant to Section 11.3 or 11.4, all licenses and
sublicenses granted by the Licensor to Alzheon hereunder (other than the licenses and sublicenses granted pursuant to Section 4.3) and each sublicense granted by Alzheon and its Affiliates hereunder shall terminate immediately and automatically
unless [ * ]. Alzheon shall immediately assign and transfer to the Licensor all of Alzheon’s right, title and interest in and to all Regulatory Approvals and other submissions to Regulatory Authorities with respect to the Licensed Product in
the Territory. Alzheon shall immediately transfer to the Licensor all the Confidential Information disclosed, transferred to it, or generated by or on behalf of the Licensor in the context of this Agreement, including all copies and extracts of
documents and all manifestations in whatever form, and all other data, if any, regarding clinical data, materials and information (including, without limitation, all sales and marketing materials) in the possession of Alzheon or one of its
Affiliates relating to the Licensed Products or the Licensed Technology. 

  

	 	(b)	 Notwithstanding any termination by Alzheon, Alzheon shall remain liable for, and shall promptly satisfy, any
and all payment obligations which accrued prior to the effective date of termination. 

  

	 	11.6.3	 Right to Sell Inventoried Licensed Products. On the date of termination, Alzheon will cease to use the
Licensed Technology or to manufacture, assemble, market, Sell, import or distribute the Licensed Products except and to the extent permitted by this Section 11.6.3: 

 

	 	(a)	 Except for a termination arising under Section 11.4, for a period not to exceed [ * ] following the date
of termination, Alzheon may Sell any Licensed Products remaining in its inventory or stock (“Inventory Sale Period”). In such case, Alzheon will deliver to Licensor an accounting within [ * ] from expiry of the Inventory Sale
Period. The accounting will specify, in or on such terms as Licensor may in its sole discretion require, the inventory or stock of Licensed Products manufactured and remaining unSold on expiry of the Inventory Sale Period. All manufactured and
remaining unsold inventory or stock of Licensed Products shall be returned to Licensor at the expiry of the Inventory Sale Period, at Licensor’s cost and sole discretion. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

31. 

	 	(b)	 Subject to Section 11.6.3(a), Licensor shall provide instructions regarding any unSold Licensed Products,
including having such Licensed Products stored, destroyed or Sold under its direction. 

  

	 	(c)	 Alzheon shall continue to make payments to Licensor in the same manner specified in Article 4 on all Licensed
Products that are Sold in accordance with this Section 11.6.3. 

  

	11.7	 Remedies. Except as otherwise expressly set forth in this Agreement, the termination provisions of this
Article 11 are in addition to any other relief and remedies available to either Party at law. 

  

	11.8	 Surviving Provisions. Notwithstanding any provision herein to the contrary, (i) the provisions of
Article 1 - Definitions, (ii) the rights and obligations of the Parties set forth in Articles 4 – Payments and Royalties, 5 - Treatment of Confidential Information, 8 – Representations and Warranties, 10 – Indemnification and
Limitation of Liability, 12 – Disputes, 13 – Miscellaneous, Section 11.6 – Effects of Termination and this Section 11.8, and (iii) any rights or obligations otherwise accrued hereunder (including any accrued payment
obligations) prior to the expiration or the effective date of termination of this Agreement, shall survive the expiration or termination of this Agreement for any reason. 

 

	12.	 DISPUTES 

  

	12.1	 Dispute Resolution Procedures. Any dispute, controversy or claim between the Parties relating to the
construction and/or interpretation of this Agreement (a “Dispute”) shall be resolved in accordance with the provisions of this Article 12. 

  

	12.2	 First Level. All Disputes (other than disputes subject to expert resolution pursuant to
Section 12.5) shall be referred to a senior representative of each Party for review, consideration and resolution. If such individuals are unable to resolve the Dispute within    [ * ] after referral of the matter to them,
then any of the Parties may by notice in writing submit the Dispute for resolution pursuant to Section 12.4. 

  

	12.3	 Mediation. If the Dispute is not resolved within the period referred to in Section 12.2, the
Parties shall attempt to resolve the Dispute with the aid of an impartial mediator who will attempt to facilitate resolution. The mediator shall be selected by agreement of the Parties. The mediation shall be treated as a settlement discussion and
therefore shall be confidential. If the Dispute has not been resolved within [ * ] after the written notice beginning the mediation process, the mediation shall terminate and the Dispute may be submitted to arbitration in accordance with
Section 12.4 within [ * ] following the termination of the mediation process by any Party by means of written notice of submission. 

  

	12.4	 Arbitration. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

32. 

	 	12.4.1	 If any Dispute is not resolved pursuant to Section 12.3, any Party may, within [ * ] after the initiation
of the procedures set forth in Section 12.3, refer such Dispute to arbitration by serving written notice of its intention to arbitrate the Dispute to the other Party. 

 

	 	12.4.2	 Arbitration of any Dispute shall be conducted in accordance with the rules of the International Chamber of
Commerce (the “ICC Rules”). Such arbitration shall be conducted by one arbitrator appointed in accordance with the ICC Rules. 

  

	 	12.4.3	 All arbitrations shall take place in the City of New York, in the State of New York, in the English language.

  

	 	12.4.4	 Any decision of the arbitrator shall be final and binding on the Parties. The costs and expenses of the
arbitration shall be paid as the arbitrator determines. The Party to whom any amount is owed as a result of an award of the arbitrator shall be entitled to payment within [ * ] of the date of award. 

 

	 	12.4.5	 Each of the Parties agrees to cooperate promptly and fully with the other Party with respect to all aspects of
arbitration, including the appointment of the arbitrator and compliance with any requests or orders of the arbitrator. 

  

	 	12.4.6	 During the arbitration proceeding, the Parties shall continue the performance of their respective obligations
hereunder in the ordinary course. 

  

	 	12.4.7	 Each Party may apply to any court of competent jurisdiction for appropriate temporary injunctive relief to
avoid irreparable harm, maintain the status quo, or preserve the subject matter of the arbitration, in each case pending resolution of any arbitration proceeding. 

 

	 	12.4.8	 EACH PARTY HERETO WAIVES ITS RIGHT TO TRIAL BY JURY OF ANY ISSUE WITHIN THE SCOPE OF THE AGREEMENT TO ARBITRATE
AS SET FORTH IN SECTION 12.4.1. 

  

	 	12.4.9	 EACH PARTY HERETO WAIVES ANY CLAIMS FOR ATTORNEYS’ FEES AND COSTS FROM THE OTHER. 

 

	12.5	 Expert Disputes. The provisions of this Section 12.5 shall apply if [ * ] the Italy
Commercialization Agreement determined by an Expert pursuant to Section 3.2.2(a). 

  

	 	12.5.1	 [ * ]. 

  

	 	12.5.2	 [ * ]. 

  

	13.	 MISCELLANEOUS 

 

	13.1	 Notification. All notices, requests and other communications hereunder shall be in writing, shall be
addressed to the receiving Party’s address set forth below or to such other address as a Party may designate by notice hereunder, and shall be either (a) 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

33. 

	 	
delivered by hand, (b) made by facsimile transmission (to be followed with written fax confirmation), (c) sent by private courier service providing evidence of receipt, or (d) sent by
registered or certified mail, return receipt requested, postage prepaid. The addresses and other contact information for the Parties are as follows: 

  

					
	If to the Licensor:    	  	FB Health S.p.A.
		  	Via dei Sabini, 28
		  	63100 Ascoli Piceno
		  	Italy	  	
			
		  	Attention:	  	Marco Marchetti, President and
		  		  	Chief Executive Officer
			
		  	Telecopier:        	  	  [ * ]
		
	If to Alzheon:	  	Alzheon, Inc.
		  	394 Lowell Street, Suite 9
		  	Lexington, MA 02420
			
		  	Attention:	  	Martin Tolar, MD, PhD, Founder, President
		  		  	and Chief Executive Officer
		  	Telecopier:	  	  [ * ]

 All notices, requests and other communications hereunder shall be deemed to have been given either (i) if
by hand, at the time of the delivery thereof to the receiving Party at the address of such Party set forth above, (ii) if made by telecopy or facsimile transmission, at the time that receipt thereof has been acknowledged by electronic
confirmation or otherwise, (iii) if sent by private courier, on the third (3rd) business day following the day such notice is delivered to the courier service, or (iv) if sent by registered or certified mail, on the fifth (5th) business
day following the day such mailing is made. 
  

	13.2	 Governing Law. This Agreement will be construed, interpreted and applied in accordance with the Laws of
the State of New York and the federal Laws of the United States of America applicable therein, excluding its body of law controlling conflicts of law. The provisions of the U.N. Convention on Contracts for the International Sale of Goods shall not
apply to this Agreement. 

  

	13.3	 Limitations. Except as expressly set forth elsewhere in this Agreement, neither Party grants to the
other Party any right or license to any of its intellectual property. All rights not expressly granted are reserved to their owners. 

  

	13.4	 Entire Agreement. This Agreement, including the Schedules and Exhibits attached hereto, and the Letter
Agreement collectively constitute the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior representations, understandings and agreements between the Parties with respect to the subject matter
hereof. No modification or amendment to this Agreement shall be effective unless in writing with specific reference to this Agreement and signed by authorized representatives of the Parties. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

34. 

	13.5	 Waiver. The terms or conditions of this Agreement may be waived only by a written instrument executed by
the Party waiving compliance. The failure of either Party at any time or times to require performance of any provision hereof shall in no manner affect its rights at a later time to enforce the same. No waiver by either Party of any condition or
term shall be deemed as a continuing waiver of such condition or term or of another condition or term. 

  

	13.6	 Headings. Section and subsection headings are inserted for convenience of reference only and do not form
part of this Agreement. 

  

	13.7	 Assignment. 

  

	 	13.7.1	 Except as otherwise provided herein, neither this Agreement nor any right or obligation hereunder may be
assigned, delegated or otherwise transferred, in whole or part, by either Party without the prior, express written consent of the other Party, which consent shall not be unreasonably withheld or delayed, except that each Party shall always have the
right, without such consent, (a) to perform any or all of its obligations and exercise any or all of its rights under this Agreement through any of its Affiliates; and (b) upon written notice to the other Party, to assign any or all of its
rights and delegate or subcontract any or all of its obligations under this Agreement to (i) any of its Affiliates or (ii) a successor of all or substantially all of assets or business to which this Agreement relates, whether by way of
merger, amalgamation, sale of stock, sale of assets or other transaction (or series of transactions). Each Party shall remain responsible for any failure to perform by any of its Affiliates to which it assigns, delegates or otherwise transfers any
rights or obligations under this Agreement in accordance with this Section 13.7.1. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment, delegation or other transfer in violation of
this Section 13.7.1 shall be void. The terms and conditions of this Agreement shall be binding upon and inure to the benefit of the permitted successors and assigns of the Parties. 

 

	 	13.7.2	 The Licensor shall not sell, assign or otherwise transfer the Bellus License Agreement or any Licensed
Technology to any Person (including any Affiliate of the Licensor) except to (x) a wholly-owned direct or indirect subsidiary of the Licensor or (y) a successor corporation or entity in accordance with Section 13.7.1(b)(ii), and
solely in each case if, prior to any such sale, assignment or transfer, such transferee has acknowledged and confirmed in writing to Alzheon that, effective as of such sale, assignment or other transfer, such transferee shall be bound by this
Agreement as if it were a party to it as and to the identical extent applicable to the Licensor with respect to the Bellus License Agreement and Licensed Technology. 

 

	13.8	 Non-Solicitation. During the Term and [ * ], neither Party
shall, directly or indirectly, through any Affiliate, officer, director, agent or otherwise, solicit for employment any employee or contractor of the other Party, provided that the hiring of such employees through the use of general
advertisements in publications shall be deemed not to violate this Section 13.8. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

35. 

	13.9	 Force Majeure. Neither Party shall be liable for failure of or delay in performing obligations set forth
in this Agreement, and neither shall be deemed in breach of its obligations, if such failure or delay is due to natural disasters or any causes beyond the reasonable control of such Party. In event of such force majeure, the Party affected thereby
shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder. 

  

	13.10	 No Third-Party Beneficiary. The terms and provisions of this Agreement are intended solely for the
benefit of each Party hereto, and it is not the intention of the Parties hereto to confer third-party beneficiary rights upon any other Person, other than the rights granted to Bellus under Section 4.5 and the Alzheon Indemnitees and the
Licensor Indemnitees in Article 10. 

  

	13.11	 Construction. The Parties hereto acknowledge and agree that: (a) each Party and its counsel have
reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the
interpretation of this Agreement; and (c) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in favor of or against any Party, regardless of which Party was generally responsible for the
preparation of this Agreement. 

  

	13.12	 Severability. If any provision(s) of this Agreement are or become invalid, are ruled illegal by any
court of competent jurisdiction or are deemed unenforceable under then current applicable Law from time to time in effect during the Term, it is the intention of the Parties that the remainder of this Agreement shall not be affected thereby provided
that a Party’s rights under this Agreement are not materially affected. The Parties hereto covenant and agree to renegotiate any such term, covenant or application thereof in good faith in order to provide a reasonably acceptable alternative to
the term, covenant or condition of this Agreement or the application thereof that is invalid, illegal or unenforceable, it being the intent of the Parties that the basic purposes of this Agreement are to be effectuated. 

 

	13.13	 Status The status of each Party under this Agreement shall be that of an independent contractor. Nothing
in this Agreement is intended or shall be deemed to constitute a partner, agency, employer-employee, or joint venture relationship between the Parties or, except as expressly provided in this Agreement, to grant either Party the authority to bind or
contract any obligation in the name of or on the account of the other Party or to make any statements, representations, warranties or commitments on behalf of the other Party. 

 

	13.14	 Further Assurances. Each Party agrees to execute, acknowledge and deliver such further instructions, and
to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

36. 

	13.15	 Counterparts. This Agreement may be executed simultaneously in one or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. 

  

	13.16	 Interpretation. Unless a context otherwise requires, wherever used, (a) the singular shall include
the plural, the plural the singular; (b) the use of any gender shall be applicable to all genders; (c) the word “or” is used in the inclusive sense (and/or); (d) the word “including” is used without limitation and shall
mean “including without limitation”; and (e) all amounts set forth in this Agreement are expressed in Canadian dollars. 

  

	13.17	 Headings. Section and subsection headings are inserted for convenience of reference only and do not form
a part of this Agreement. 

 [signature page follows] 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

37. 

 Execution Version 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representative in originals. 

 

									
	ALZHEON, INC.	 		 	FB HEALTH S.p.A.
					
	Per:	 	/s/ Martin Tolar	 		 	Per:	 	/s/ Marco Marchetti
	Name:	 	Martin Tolar, MD, PhD	 		 	Name:	 	Marco Marchetti
	Title:	 	Founder, President and Chief Executive Officer	 		 	Title:	 	President and Chief Executive Officer

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 SCHEDULE A 

Licensed Patents 
 [*] 

(Expiry December 2025) 
 [*] 

(Expiry June 2024) 
 [*] 

(Expiry April 2020) 
 [*] 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 SCHEDULE B 

BLU8499 Patents 
 [ * ]

 (Expiry October 2027) 
 [ * ]

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 SCHEDULE C 

Excluded Disorders, Conditions and Diseases 

[ * ] 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT A 

Terms of Italy Commercialization Agreement 

[ * ] 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 AMENDMENT NO. 1 TO 

LICENSE AGREEMENT 
 This Amendment
No. 1 to License Agreement (this “Amendment”), effective as of February 27, 2015 (the “Amendment Effective Date”), amends the License Agreement effective as of October 22, 2013 by and between FB
Health S.p.A., a company organized and existing under the laws of Italy (“Licensor”), and Alzheon, Inc., a Delaware (USA) corporation (“Alzheon”) (the “Agreement”). Capitalized terms used herein and
not otherwise defined shall have the meanings ascribed to them in the Agreement. 
 WHEREAS Licensor and Alzheon desire to amend, in
accordance with Section 13.4 of the Agreement, various aspects of the Agreement to, among other things: (i) expand the defined field of Alzheon’s licenses for certain Licensed Products; and (ii) modify certain specific diligence
requirements. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein and for other good and valuable consideration,
Licensor and Alzheon, intending to be legally bound, hereby agree that, as of the Amendment Effective Date: 
 1. Section 1 of the Agreement
is hereby amended by: 
 a. inserting the following definitions in the appropriate alphabetical locations: 

““ALZ-801 Compound” means the compound identified as such on Schedule D attached
hereto and referred to by Alzheon as of the Amendment Effective Date as ALZ-801. For clarity, the ALZ-801 Compound is not Tramiprosate.” 

““ALZ-801 Licensed Product” means each Licensed Product that contains
(i) the ALZ-801 Compound and/or (ii) any prodrug, analog, salt, free acid, free base, clathrate, solvate, hydrate, hemihydrate, anhydride, ester, chelate, conformer, congener, crystal form, crystal
habit, polymorph, amorphous solid, homolog, isomer, stereoisomer, enantiomer, racemate, isotopic or radiolabeled equivalent, metabolite or conjugate of the ALZ-801 Compound; provided that the compounds
described in subsection (ii) shall exclude Tramiprosate. Notwithstanding anything to the contrary in this Agreement, if a Licensed Product falls within the definition of both an ALZ-801 Licensed Product
and a Tramiprosate Licensed Product, it will be an ALZ-801 Licensed Product. 

““Tramiprosate” means the compound identified as such on Schedule D attached hereto and referred to by Alzheon as of the
Amendment Effective Date as tramiprosate.” 
 ““Tramiprosate Licensed Product” means each Licensed Product that
contains (i) Tramiprosate and/or (ii) any analog, salt, free acid, free base, clathrate, solvate, hydrate, hemihydrate, anhydride, ester, chelate, conformer, congener, crystal form, crystal

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
habit, polymorph, amorphous solid, homolog, isomer, stereoisomer, enantiomer, racemate, isotopic or radiolabeled equivalent, metabolite or conjugate of Tramiprosate. Notwithstanding anything to
the contrary in this Agreement, if a Licensed Product falls within the definition of both an ALZ-801 Licensed Product and a Tramiprosate Licensed Product, it will be an
ALZ-801 Licensed Product.” 
 b. deleting the definition of “Field” in its entirety
and replacing it with the following definition: 
 ““Field” shall mean: 

(a) as applied to the ALZ-801 Compound and
ALZ-801 Licensed Products, any and all uses, excluding any use in the mitigation, prevention, treatment, control or diagnosis of AA Amyloidosis; 

(b) as applied to Tramiprosate and Tramiprosate Licensed Products, any and all uses excluding (i) any use within the
Vivimind Field, and (ii) any use in the mitigation, prevention, treatment, control or diagnosis of AA Amyloidosis; and 

(c) as applied to any Licensed Products other than the ALZ-801 Licensed Products and
the Tramiprosate Licensed Products, the mitigation, prevention, treatment, control or diagnosis of any disorder, condition or disease that is caused by a disorder of the central nervous system and/or the peripheral nervous system, including
Alzheimer’s disease, Parkinson’s disease, Multiple sclerosis, Huntington’s disease, Amyotrophic lateral sclerosis and any other neuropsychiatric or neurodegenerative diseases of the central nervous system and/or the peripheral nervous
system. For avoidance of doubt, the Field specifically excludes the Vivimind Field as well as the mitigation, prevention, treatment, control or diagnosis of any disorder, condition or diseases that are not caused by disorders of the central nervous
system or the peripheral nervous system, and/or the disorders, conditions and diseases listed on Schedule C hereto. 
 c. adding the
following sentence to the end of the existing definition of “Licensed Product” 
 ““For clarity, Licensed Products
include ALZ-801 Licensed Products and Tramiprosate Licensed Products.” 
 2. Section 2.2 of the
Agreement is hereby amended by deleting the text thereof in its entirety and replacing it with the following: 
 “Restriction to
License. For avoidance of doubt, the Parties agree that: 
 a. Alzheon is not granted any rights hereunder to use, have used, Develop,
have Developed, make, have made, modify, have modified, enhance, have enhanced, improve, have improved the Licensed Technology or the Licensed Products outside the Field, or to manufacture, have manufactured, market, sell, offer for sale, have sold,
import, have imported, distribute or have distributed the Licensed Products outside the Field; 
 b. Licensor shall retain no rights to use,
have used, Develop, have Developed, make, have made, modify, have modified, enhance, have enhanced, improve, have improved the ALZ-801 Compound, or Tramiprosate, the Licensed Technology or the Licensed
Products for the Field, or to manufacture, have manufactured, market, sell, offer for sale, have sold, import, have imported, distribute or have distributed, the ALZ-801 Compound, Tramiprosate or the Licensed
Products in the Field; and 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 c. Licensor shall not, during the Term, Develop, have Developed, manufacture, have manufactured,
market, sell, offer for sale, have sold, import, have imported, distribute or have distributed any compound or product for the mitigation, prevention, treatment, control or diagnosis of AA Amyloidosis, or cause or assist, directly or indirectly, any
Third Party to do any of the foregoing acts.” 
 3. Section 3.1.2 of the Agreement is hereby amended by deleting the text thereof in
its entirety and replacing it with the following: 
 “Alzheon Diligence Obligations. In accordance with Section 2.3
of the Bellus License Agreement, Alzheon shall fully satisfy, on behalf of the Licensor, the following obligations: 
 (a)
during the Term, Alzheon shall use Commercially Reasonable Efforts to Develop at least one Licensed Product in the Field in the Territory, and after obtaining Regulatory Approval therefor, to commercialize such Licensed Product in the Field; 

(b) Alzheon shall, or shall cause one of its sublicensees to, dose the first healthy individual in any study of a Licensed
Product in the Field no later than the third (3rd) anniversary of the Effective Date; and  

(c) Alzheon shall, or shall cause one of its sublicensees to, dose the first patient in a clinical trial of a Licensed Product
in the Field no later than the fourth (4th) anniversary of the Effective Date.”  

4. Section 3.4 of the Agreement is hereby amended by deleting the text thereof in its entirety and replacing it with the following: 

“Ownership of Submissions and Regulatory Approvals. Subject to Section 11.6, Alzheon shall own all Regulatory Approvals for
Licensed Products and any other submissions to any Regulatory Authority with respect to Licensed Products in the Field in the Territory.” 

5. Section 13.1 of the Agreement is hereby amended by deleting the address for notices to Alzheon and replacing it with the following: 

 

			
	 If to Alzheon:
	  	Alzheon, Inc.
		  	111 Speen Street, Suite 306
		  	Framingham, MA 01701
		  	Attention:        Martin Tolar, M.D., Ph.D.
		  	                         President and CEO
		  	Telecopier: [ * ]

 6. The Agreement is hereby amended by attaching Schedule D attached hereto as new Schedule D to the Agreement.

 7. As consideration for the entering into of this Amendment, Alzheon hereby agrees to issue 72,992 of its common shares (on the same
terms and conditions as its most recent financing completed on February 12, 2015 (as adjusted to reflect any consolidation, share split or other share reorganization completed since that date by Alzheon)) to a designee of Licensor, which shall
be BHI Limited Partnership. For avoidance of doubt, such shares shall represent a payment amount equal to [ * ]. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 8. Except as expressly amended by this Amendment, all of the terms and conditions of the
Agreement shall remain in full force and effect. 
 9. This Amendment will be construed, interpreted and applied in accordance with the Laws
of the State of New York and the federal Laws of the United States of America applicable therein, excluding its body of law controlling conflicts of law. The provisions of the U.N. Convention on Contracts for the International Sale of Goods shall
not apply to this Amendment. 
 10. This Amendment may be executed simultaneously in one or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. 
 [Signature Page follows] 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF Licensor and Alzheon have executed this Amendment as of the respective dates set forth below.

  

			
	ALZHEON, INC.	  	FB HEALTH S.p.A.
		
	By: /s/ Martin Tolar	  	By: /s/ Marco Marchetti
	Name: Martin Tolar	  	Name: Marco Marchetti
	Title: President and CEO	  	Title: Chief Executive Officer
		
	Date: February 27, 2015	  	Date: February 26, 2015

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Schedule D 

DESCRIPTION OF THE ALZ-801 COMPOUND and TRAMIPROSATE 

 

					
	 Tramiprosate
  

Chemical IUPAC Name: 
3-amino-1-propanesulfonate
  

 
 Structural Formula:

 
 

	 		  	 ALZ-801 Compound

 
 Chemical IUPAC Name: 3-(2-amino-3-methylbutanamido)propane-1-sulfonic
acid)
  
 Structural Formula:

 
 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

			
	 CONFIDENTIAL
 COPY
	  	EXECUTION

 AMENDMENT NO. 2 TO 

LICENSE AGREEMENT 
 This Amendment
No. 2 to License Agreement (this “Second Amendment”), effective as of June 30, 2016 (the “Second Amendment Effective Date”), amends the License Agreement effective as of October 22, 2013 by and
between FB Health S.p.A., a company organized and existing under the laws of Italy (“Licensor”), and Alzheon, Inc., a Delaware (USA) corporation (“Alzheon”), as previously amended by Amendment No. 1 effective
as of February 27, 2015 (collectively, the “Agreement”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Agreement. 

WHEREAS Licensor and Alzheon desire to further amend the Agreement in accordance with Section 13.4 of the Agreement. 

NOW, THEREFORE, in consideration of the mutual covenants contained herein and for other good and valuable consideration, Licensor and Alzheon,
intending to be legally bound, hereby agree that, as of the Second Amendment Effective Date: 
 1. Section 1 of the Agreement is hereby
amended by: 
 a. Inserting the following definition in the appropriate alphabetical location: 

““Improvement Licensed Product” means a product, the composition of matter, manufacture or use of which is claimed in a
Pending Claim or Valid Claim of a Patent Right included in part (ii) of the definition of “Licensed Patent Rights”.” 

b. deleting the definition of “Field” in its entirety and replacing it with the following definition: 

““Field” shall mean: 

(a) as applied to the ALZ-801 Compound, ALZ-801
Licensed Products and, subject to the proviso below, Improvement Licensed Products, any and all uses, excluding any use in the mitigation, prevention, treatment, control or diagnosis of AA Amyloidosis; 

(b) as applied to Tramiprosate and Tramiprosate Licensed Products, any and all uses excluding (i) any use within the Vivimind
Field, and (ii) any use in the mitigation, prevention, treatment, control or diagnosis of AA Amyloidosis; and 
 (c) as
applied to any Licensed Products other than the ALZ-801 Licensed Products, Tramiprosate Licensed Products and, to the extent set forth in the proviso below, Improvement Licensed Products, the mitigation,
prevention, treatment, control or diagnosis of any disorder, condition or disease that is caused by a disorder of the central nervous system and/or the peripheral nervous system, including Alzheimer’s disease, Parkinson’s disease, Multiple
sclerosis, Huntington’s disease, Amyotrophic lateral sclerosis and any other neuropsychiatric or neurodegenerative diseases of the central nervous system and/or the peripheral nervous system. For avoidance of doubt, the Field specifically
excludes the Vivimind Field as well as the mitigation, prevention, treatment, control or diagnosis of any disorder, condition or diseases that are not caused by disorders of the central nervous system or the peripheral nervous system, and/or the
disorders, conditions and diseases listed on Schedule C hereto.; 
 c. deleting the last sentence at the end of the existing definition of
“Licensed Product” and replacing it with the following: 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
“For clarity, Licensed Products include ALZ-801 Licensed Products, Tramiprosate Licensed Products and Improvement Licensed Products.” 

2. Section 2.2(c) of the Agreement is hereby amended by deleting the text thereof in its entirety and replacing it with the following: 

“Licensor and its Affiliates shall not, during the Term, Develop, have Developed, manufacture, have manufactured, market, sell, offer for
sale, have sold, import, have imported, distribute or have distributed any Licensed Product for the mitigation, prevention, treatment, control or diagnosis of [ * ], or cause or assist, directly or indirectly, any Third Party to do any of the
foregoing acts.” 
 3. Section 3.1.2 of the Agreement is hereby amended by deleting the text thereof in its entirety and replacing it
with the following: 
 “Alzheon Diligence Obligations. In accordance with Section 2.3 of the Bellus License Agreement, Alzheon
shall fully satisfy, on behalf of the Licensor, the following obligations: 
 (a) during the Term, Alzheon shall use
Commercially Reasonable Efforts to Develop at least one Licensed Product in the Field in the Territory, and after obtaining Regulatory Approval therefor, to commercialize such Licensed Product in the Field; 

(b) Alzheon shall, or shall cause one of its sublicensees to, dose the first healthy individual in any study of a Licensed
Product in the Field no later than the third (3rd) anniversary of the Effective Date; and 

(c) Alzheon shall, or shall cause one of its sublicensees to, dose the first patient in a clinical trial of a Licensed Product
in the Field no later than the fifth (5th) anniversary of the Effective Date.” 

4. Section 3.1.3 of the Agreement is hereby amended by deleting the text thereof in its entirety and replacing it with the following: 

“Arising Intellectual Property. During the Term, all right, title and interest in and to any enhancement, invention or
discovery created, conceived, identified, or reduced to practice by Alzheon, by any of its Affiliates, by a Third Party on behalf of Alzheon, or by any sublicensee, that relies on or incorporates the Licensed Technology (an
“Improvement”) [ * ].” 
 5. Section 11.6.1(a) of the Agreement is hereby amended by deleting the text thereof in its
entirety and replacing it with the following: 
 “(a) Upon any termination of this Agreement by the Licensor hereunder or any
termination of this Agreement by Alzheon pursuant to Section 11.5, as of the effective date of such termination, all licenses and sublicenses granted by the Licensor to Alzheon hereunder (other than the licenses and sublicenses granted pursuant
to Section 4.3) shall terminate immediately and automatically. Each sublicense granted directly to a Third Party by Alzheon or its Affiliate that is then in effect shall survive termination as if granted directly by Licensor to the applicable
sublicensee, provided that (i) such sublicense was granted in compliance with Section 2.3, (ii) [ * ]. Alzheon shall immediately assign and transfer to the Licensor, [ * ], all of Alzheon’s and its Affiliates’ right, title and
interest in and to all Regulatory Approvals and other submissions to Regulatory Authorities with respect to the Licensed Products in the Territory. Alzheon shall immediately transfer to the Licensor all the Confidential Information disclosed,

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
transferred to it, or generated by or on behalf of the Licensor in the context of this Agreement, including all copies and extracts of documents and all manifestations in whatever form, and all
other data, if any, regarding clinical data, materials and information (including, without limitation, all sales and marketing materials) in the possession of Alzheon or one of its Affiliates relating to the Licensed Products or the Licensed
Technology.” 
 6. Section 11.6.2(a) of the Agreement is hereby amended by deleting the text thereof in its entirety and replacing it
with the following: 
 “(a) Upon any termination of this Agreement by Alzheon pursuant to Section 11.3 or 11.4, all licenses and
sublicenses granted by the Licensor to Alzheon hereunder (other than the licenses and sublicenses granted pursuant to Section 4.3) hereunder shall terminate immediately and automatically. Each sublicense granted directly to a Third Party by
Alzheon or its Affiliate that is then in effect shall survive termination as if granted directly by Licensor to the applicable sublicensee, provided that (i) such sublicense was granted in compliance with Section 2.3 (ii) [ * ]. Alzheon
shall immediately assign and transfer to the Licensor all of Alzheon’s and its Affiliates’ right, title and interest in and to all Regulatory Approvals and other submissions to Regulatory Authorities with respect to the Licensed Product in
the Territory. Alzheon shall immediately transfer to the Licensor all the Confidential Information disclosed, transferred to it, or generated by or on behalf of the Licensor in the context of this Agreement, including all copies and extracts of
documents and all manifestations in whatever form, and all other data, if any, regarding clinical data, materials and information (including, without limitation, all sales and marketing materials) in the possession of Alzheon or one of its
Affiliates relating to the Licensed Products or the Licensed Technology.” 
 7. Except as expressly amended by this Second Amendment,
all of the terms and conditions of the Agreement shall remain in full force and effect. From and after the Second Amendment Effective Date, all references to the Agreement shall mean the Agreement as amended by this Second Amendment. 

8. This Second Amendment will be construed, interpreted and applied in accordance with the Laws of the State of New York and the federal Laws
of the United States of America applicable therein, excluding its body of law controlling conflicts of law. The provisions of the U.N. Convention on Contracts for the International Sale of Goods shall not apply to this Second Amendment. 

9. This Second Amendment may be executed simultaneously in one or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. 
 [Signature Page Follows] 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF Licensor and Alzheon have executed this Second Amendment as of the respective dates set forth
below. 
  

									
	ALZHEON, INC.	 		 	FB HEALTH S.p.A.
					
	Per:	 	/s/ Martin Tolar	 		 	Per:	 	/s/ Marco Marchetti
	Name:	 	Martin Tolar, MD, PhD	 		 	Name:	 	Marco Marchetti
	Title:	 	Founder, President and Chief Executive Officer	 		 	Title:	 	President and Chief Executive Officer

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]